

NHS BLOOD AND TRANSPLANT

NATIONAL LIVER OFFERING SCHEME

SIXTY MONTH REVIEW

SUMMARY

1. BACKGROUND

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity.
- 1.2. It should be noted that this report may not include all data due to delays in reporting.
- 1.3. Updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in **Figure 9B**.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and the changes to the DBD offering scheme ceased on 9 July 2020 when named patient offering recommenced. This period is excluded from part of the liver offering section.
- 1.5. The estimates used to calculate the Transplant Benefit Score (TBS) were updated on 4 October 2022 and the offering data has been presented separately for 2022/2023.

2. DATA AND METHODS

- 2.1. **Table S1** shows the time period and inclusion and exclusion criteria for the aspects of the offering scheme examined in this report. NHS Group 2 registrations and transplants were excluded throughout the report along with registrations, offers and transplants for intestinal patients not requiring a liver. Super-urgent and elective registrations were included in all aspects apart from the transplant list activity section as were adult and paediatric registrations and transplants. All full year time periods are 20 March to 19 March.

Table S1 Inclusion and exclusion criteria for the aspects of NLOS examined in this report			
Section	Time period	Inclusions	Exclusions
Registration activity	<ul style="list-style-type: none"> 20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=1169) 20 March 2018 to 19 March 2023 (<i>sixty months post</i>, N=5906) 	<ul style="list-style-type: none"> New active/suspended registrations 	<ul style="list-style-type: none"> Dublin registrations NHS Group 2 registrations
One and three month post-registration outcome	<ul style="list-style-type: none"> 20 December 2016 to 19 December 2017 (<i>Year prior</i>, N=945) 20 March 2018 to 19 December 2022 (<i>fifty-seven months post</i>, N=4611) 	<ul style="list-style-type: none"> Active and suspended Adult elective liver and liver/kidney registrations 	<ul style="list-style-type: none"> Dublin registrations NHS Group 2 registrations Intestinal registrations
Six months post-registration outcome	<ul style="list-style-type: none"> 20 September 2016 to 19 September 2017 (<i>Year prior</i>, N=906) 20 March 2018 to 19 September 2022 (<i>fifty-four post</i>, N=4332) 	<ul style="list-style-type: none"> Active and suspended Adult elective liver and liver/kidney registrations 	<ul style="list-style-type: none"> Dublin registrations NHS Group 2 registrations Intestinal registrations
One-year post-registration outcome	<ul style="list-style-type: none"> 20 March 2016 to 19 March 2017 (<i>Year prior</i>, N=924) 20 March 2018 to 20 March 2022 (<i>forty-eight post</i>, N=3828) 	<ul style="list-style-type: none"> Active and suspended Adult elective liver and liver/kidney registrations 	<ul style="list-style-type: none"> Dublin registrations NHS Group 2 registrations Intestinal registrations
Liver offering	<ul style="list-style-type: none"> <i>Year prior</i>, N=1914 (962 DBD and 952 DCD) <i>Sixty months post</i>, N=8720 (4367 DBD and 4353 DCD) 	<ul style="list-style-type: none"> UK deceased donors whose liver was offered for transplantation Offers to Dublin for super-urgent patients 	<ul style="list-style-type: none"> Intestinal offers regardless of whether patients required a liver Offers declined due to the patient accepting previously offered liver Offers to Dublin for elective patients
Transplant activity	<ul style="list-style-type: none"> 20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=1017, 819 DBD and 198 DCD) 20 March 2018 to 19 March 2023 (<i>Sixty months post</i>, N=4410 (3485 DBD and 925 DCD)) 	<ul style="list-style-type: none"> UK transplants 	<ul style="list-style-type: none"> Transplants performed at Dublin Intestinal transplants for patients not requiring a liver NHS Group 2 transplants
Ninety-day post-transplant survival	<ul style="list-style-type: none"> 20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=579 for DBD and 183 for DCD) 20 March 2018 to 19 December 2022 (<i>fifty-seven months post</i>, N=2295 for DBD and 804 for DCD) 	<ul style="list-style-type: none"> UK adult elective liver and liver/kidney transplants 	<ul style="list-style-type: none"> Transplants performed at Dublin Intestinal transplants for patients not requiring a liver NHS Group 2 transplants
One-year post-transplant survival	<ul style="list-style-type: none"> 20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=579 for DBD and 183 for DCD) 20 March 2018 to 19 March 2022 (<i>forty-eight months post</i>, N=1769 for DBD and 532 for DCD) 	<ul style="list-style-type: none"> UK adult elective liver and liver/kidney transplants 	<ul style="list-style-type: none"> Transplants performed at Dublin Intestinal transplants for patients not requiring a liver NHS Group 2 transplants

3. RESULTS

REGISTRATION ACTIVITY

- 3.1. There were 5906 new NHS Group 1 liver registrations in the UK in the first sixty months of the scheme. **(Table 1)**
- 3.2. The proportion of elective liver registrations decreased slightly from 88.5% to 88.2% between the 2017/2018 and 2022/2023. The proportion of adult elective registrations with CLD has increased from 71% in 2017/2018 to 73% in 2022/2023 but the proportion of HCC registrations (including HCC downstaging) has decreased by 3%. The number of new variant syndrome registrations has increased from 63 in 2021/22 to 83 in 2022/2023. **(Table 3)**
- 3.3. Ninety-three percent of the new adult elective registrations in 2022/2023 were for first graft compared with 91% in 2017/2018. **(Table 4)**
- 3.4. The median age of new adult elective registrations increased from 55 in 2017/2018 to 56 in 2022/2023. **(Table 5)**

POST-REGISTRATION OUTCOME

- 3.5. There were 4611 adult elective registrations in the subset of patients registered in the first 57 months post-NLOS. The proportion of registrations who received a transplant within three months of registration ranged from 37% to 52% across the yearly time periods post NLOS. **(Table 6)**
- 3.6. The proportion of patients who either died on the list or were removed due to condition deterioration in the first three months ranged from 3% to 5% in the time periods post NLOS compared to 6% in the time period prior. In the six-month registration outcome time periods, the proportion of patients who either died on the list or were removed due to condition deterioration ranged from 4% to 9% in the time periods post NLOS compared to 8% in the time period prior. **(Figures 6 and B4)**

LIVER OFFERING

- 3.7. Overall, 4367 DBD livers and 4353 DCD livers were offered in the first sixty months of the scheme. For DBD donors, the proportion retrieved ranged between 85% and 90% in the 60 months post and 88% in the year prior to NLOS. The equivalent proportion for DCD was 26% to 41% for the 60 month post and 32% in the year prior to NLOS. **(Table 8)**
- 3.8. **Figures 9a** and **9b** in the main paper show the number of DBD livers offered during the first sixty months at each stage of the liver offering pathway. Livers offered during COVID are included in **Figure 9a** but excluded at the elective stage of **Figure 9b**. Six hundred and fifty three livers were either accepted and transplanted or declined and not offered on prior to the elective section of the offering pathway.

- 3.9. Of the 3509 DBD livers offered to the elective section that were not offered only to paediatric centres and not offered during the first wave of COVID-19 in 2020, 3159 (90%) were allocated to the elective CLD/HCC pathway and 350 (10%) were randomly allocated to the variant syndrome pathway which is consistent with the percentages used in the probabilistic prioritisation of the elective list.
- 3.10. 1696 livers (not accepted by higher tiers) offered to named elective CLD/HCC were accepted and transplanted while 137 livers offered to the named elective variant syndrome pathway were accepted and transplanted.
- 3.11. 1442 livers declined by all stages were fast-tracked and 562 were accepted and transplanted.
- 3.12. 7006 (35%) of the 20006 offers made in the first 60 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 4895 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.13. The number of named patient offers per donor ranged between 1 and 18 with a median of two named patient offers per donor. The number of named offers per patient ranged between 1 and 27 with a median of two offers per patient. Forty four patients at 7 centres were offered 11 or more livers in the sixty month time period (15 were offered 11 livers, 9 were offered 12 livers, 5 were offered 13 livers, 6 were offered 14 livers, 1 was offered 15 livers, 2 were offered 17, 1 was offered 18 livers, 1 was offered 19 livers, 1 was offered 21 and 3 were offered 27 livers).

TRANSPLANT ACTIVITY

- 3.14. The proportion of super-urgent transplants performed has increased from prior to NLOS implementation to 2022/23 (11% vs 14% respectively). There were 109 DBD super-urgent transplants pre NLOS 2017/2018 and 122 DBD super-urgent transplants in 2022/2023. (**Table 14**)
- 3.15. One hundred and forty of the 3676 adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the transplant section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients.
- 3.16. For DBD transplants, there was evidence of a statistically significant association between time period and disease group ($p=0.002$), transplant centre ($p=0.014$), zonal ($p<0.0001$), type of patient ($p<0.0001$) and blood group compatibility ($p<0.0001$). (**Table 15**).
- 3.17. For DCD transplants, there was evidence of a statistically significant association between time period and disease group ($p=0.017$), transplant centre ($p<0.0001$) and type of patient ($p=0.015$).

There was no significance for blood group compatibility ($p=0.10$), similarly with association for zonal transplants ($p=0.72$). (**Table 16**).

- 3.18. There was a statistically significant difference in cold ischaemia time for both adult elective DBD ($p=0.004$) and DCD ($p=0.014$) transplants across the time periods of interest. However, this may be due to the inclusion of periods of machine perfusion which is not currently collected on the liver transplant record form. (**Figure 16-19**)
- 3.19. There was no significant difference in ninety-day DBD and DCD patient survival (p -value= 0.33 and 0.08 respectively). (**Figure 20**). There was no significant difference at a 5% significance level in ninety-day transplant survival for either DBD or DCD transplants (p -value= 0.49 and 0.45 respectively). (**Figure 21**).
- 3.20. There was no significant difference in one-year DBD and DCD patient survival (p -value= 0.58 and 0.6 respectively). (**Figure 22**). There was no significant difference at a 5% significance level in one-year transplant survival for either DBD or DCD transplants (p -value= 0.7 and 0.7 respectively). (**Figure 23**).

NHS BLOOD AND TRANSPLANT

NATIONAL LIVER OFFERING SCHEME

SIXTY MONTH REVIEW

1. BACKGROUND

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity. All full year time periods are 20 March to 19 March.
- 1.2. It should also be noted that this report may not include all data due for the first sixty months due to delays in reporting.
- 1.3. The updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in **Figure 9B**.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and NLOS resumed on 9 July 2020.
- 1.5. Birmingham, Royal Free, Kings College and Cambridge temporarily closed for all adult transplants in December 2020/January 2021. Royal Free and Birmingham temporarily transferred some of their clinically urgent patients to other transplant centres who were open. Transplant centres reviewed their transplant lists in January 2021 and formally suspended non-urgent patients. Offering to named clinically urgent patients continued and centres could consider livers for non-urgent patients if declined for all clinically urgent patients.
- 1.6. All transplant centres other than Birmingham formally reactivated all non-urgent CLD and HCC patients on the 6th April 2021 while variant syndrome patients and patients at Birmingham were reactivated in late April 2021.

- 1.7. Birmingham closed for all DCD offers in January 2021 with Newcastle and Leeds receiving Birmingham's zonal and linked offers on a rota basis. Birmingham reopened for DCD offers in late April 2021.
- 1.8. The parameter estimates and baseline survivor functions used to calculate the TBS were updated on 4 October 2022 and are included in this report from 4 October 2022 to 19 March 2023.

2. DATA AND METHODS

2.1. REGISTRATION ACTIVITY AND POST-REGISTRATION OUTCOME

- 2.1.1. Data on 7075 new active/suspended NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 March 2023 were obtained from the UK Transplant Registry on 13 April 2023. Patients registered in Dublin or as NHS Group 2 were excluded as such elective patients would only be offered a liver if all UK transplant centres declined the offer.
- 2.1.2. One and three month registration outcome was examined for registrations either between 20 December 2016 and 19 December 2017 (N=945) or between 20 March 2018 and 19 December 2022 (N=4611).
- 2.1.3. Six month registration outcome was also examined for a subset registered either between 20 September 2016 and 19 September 2017 (N=906) or between 20 March 2018 and 19 September 2022 (N=5238).

2.2. LIVER OFFERING

- 2.2.1. Data on 9785 deceased donors (4937 DBD and 4848 DCD) from the UK whose liver was offered for transplantation between 20 March 2017 and 19 March 2023 were obtained from the UK Transplant Registry on 27 April 2023. Intestinal offers were excluded regardless of whether they required a liver or not. The data was split into seven year periods.

2.3. TRANSPLANT ACTIVITY AND POST-TRANSPLANT SURVIVAL

- 2.3.1. Data on 5427 deceased donor liver transplants (4304 DBD and 1123 DCD) performed in the UK between 20 March 2017 and 19 March 2023 were also obtained from the UK Transplant Registry on 27 April 2023. Intestinal transplants involving the liver were included.

3. RESULTS

3.1. REGISTRATION ACTIVITY - OVERALL

3.1.1. **Figure 1** shows the number of new NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 March 2023 by quarter and urgency status while **Table 1** compares the twelve months pre the introduction of NLOS and the sixty months post the introduction of NLOS. There was no statistically significant association between the time of registration and registration type (Chi-squared p-value =0.19). It should be noted that there was an increase in the number of paediatric acute liver failure patients in the first two quarters of 2022.




Table 1

Urgency status by time period for all NHS Group 1 liver registrations in the UK, 20 March 2017 to 19 March 2023

Urgency status	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	Total
Elective	1035 (89)	1075 (88)	1065 (89)	909 (90)	1114 (91)	1109 (88)	6307 (89)
Super-urgent	134 (11)	140 (12)	132 (11)	104 (10)	109 (9)	149 (12)	768 (11)
Total	1169 (100)	1215 (100)	1197 (100)	1013 (100)	1223 (100)	1258 (100)	7075 (100)

3.2. REGISTRATION ACTIVITY - SUPER-URGENT

3.2.1. **Table 2** compares the twelve months pre the introduction of NLOS and the sixty months post the introduction of NLOS by super-urgent category. The proportion of patients registered as either category 8 (HAT on days 0 to 21) or 9 (Early graft dysfunction on days 0 to 7) was 26% in the year prior and ranged between 18% and 23% in the years post NLOS. **Appendix A** shows the descriptions of each of the categories.

Super-urgent category	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	Total
1	2 (1)	3 (2)	4 (3)	3 (3)	5 (5)	5 (3)	22 (3)
2	11 (8)	10 (7)	11 (8)	5 (5)	5 (5)	14 (9)	56 (7)
3	4 (3)	9 (6)	6 (5)	9 (9)	7 (6)	8 (5)	43 (6)
4	2 (1)	2 (1)	2 (2)	3 (3)	4 (4)	1 (1)	14 (2)
5	11 (8)	5 (4)	3 (2)	4 (4)	8 (7)	10 (7)	41 (5)
6	54 (40)	56 (40)	50 (38)	41 (39)	40 (37)	59 (40)	300 (39)
7	6 (4)	3 (2)	9 (7)	8 (8)	10 (9)	10 (7)	46 (6)
8	22 (16)	19 (14)	14 (11)	9 (9)	8 (7)	19 (13)	91 (12)
9	13 (10)	20 (14)	15 (11)	11 (11)	12 (11)	10 (7)	81 (11)
10	4 (3)	4 (3)	6 (5)	0 (0)	0 (0)	1 (1)	15 (2)
20	3 (2)	5 (4)	7 (5)	6 (6)	5 (5)	5 (3)	31 (4)
88	2 (1)	4 (3)	5 (4)	5 (5)	5 (5)	7 (5)	28 (4)
Total	134 (100)	140 (100)	132 (100)	104 (100)	109 (100)	149 (100)	768 (100)

3.3. REGISTRATION ACTIVITY - ELECTIVE

3.3.1. **Table 3** compares the twelve months pre the introduction of NLOS and the sixty months post the introduction of NLOS for NHS Group 1 elective registrations by age and type of patient. There was no statistically significant association between patient age group and time period (Chi-squared p-value =0.62).

Type of patient	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	Total
Overall							
<i>Adult elective¹</i>	951 (92)	990 (92)	980 (92)	826 (91)	1037 (93)	1017 (92)	5801 (92)
CLD	674 (71)	721 (73)	739 (75)	637 (77)	788 (76)	746 (73)	4304 (74)
HCC/ HCC downstaging Variant syndrome	193 (20)	195 (20)	178 (18)	147 (18)	167 (16)	170 (17)	1050 (18)
ACLFLiver/ cardiothoracic	83 (9)	71 (7)	56 (6)	38 (5)	63 (6)	83 (8)	394 (7)
	0 (0)	1 (0)	2 (0)	2 (0)	13 (1)	15 (1)	34 (1)
	1 (0)	2 (0)	5 (1)	2 (0)	6 (1)	3 (0)	19 (0)
<i>Paediatric elective²</i>	84 (8)	85 (8)	85 (8)	83 (9)	77 (7)	92 (8)	506 (8)
Hepatoblastoma/ Prioritised Paediatric Non hepatoblastoma	3 (4)	10 (12)	10 (12)	21 (25)	16 (21)	18 (20)	78 (15)
Liver/ cardiothoracic	81 (96)	74 (87)	75 (88)	62 (75)	59 (77)	74 (80)	425 (84)
	0 (0)	1 (1)	0 (0)	0 (0)	2 (3)	0 (0)	3 (1)

¹ Includes 19 CLD, 1 HCC and 2 Variant syndrome patient aged 17 years or over and weighing 40kg or under (1 in the twelve months prior and 21 in the sixty months post); 15 were dual-listed as small adults (1 in the twelve months prior and 14 in the sixty months post)

² Includes 6 hepatoblastoma and 86 non hepatoblastoma patients aged less than 17 years and weighing 40kg or over (20 in the twelve months prior and 72 in the sixty months post); 69 were dual-listed as large paediatrics (5 in the twelve months prior and 64 in the sixty months post)

3.3.2. **Table 4** compares the twelve months pre and the sixty months post the introduction of NLOS for each type of adult patient registered over the last 72 months by transplant number. The majority of patients were registered for a first liver transplant and there were no statistically significant associations between whether patient was registered for a first transplant or not and the time period (Chi-squared p-value=0.29).

3.3.3. All but three of the HCC patients were registered for a first graft. All patients registered for a second graft had a UKELD less than 49 and no current ascites; two patients had encephalopathy grade 0 and one had encephalopathy grade 1.

Table 4 Transplant number by time period for adult elective registrations in the UK, 20 March 2017 to 19 March 2023

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	Total
CLD¹ (Chi-squared p-value=0.26)							
1 st graft	597 (89)	652 (90)	655 (89)	570 (89)	721 (92)	679 (91)	3874 (90)
2 nd graft	64 (9)	57 (8)	71 (9)	57 (9)	48 (6)	56 (8)	353 (8)
3 rd graft	9 (1)	12 (2)	11 (1)	9 (1)	16 (2)	10 (1)	67 (2)
4 th graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	9 (0)
6 th graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
HCC/HCC downstaging² (Fishers exact p-value=0.97)							
1 st graft	192 (99)	194 (99)	178 (100)	147 (100)	167 (100)	169 (99)	1047 (100)
2 nd graft	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	3 (0)
Variant syndrome³ (Fishers exact p-value=0.05)							
1 st graft	73 (88)	61 (86)	55 (98)	35 (92)	59 (94)	80 (96)	363 (92)
2 nd graft	10 (12)	10 (14)	0 (0)	3 (8)	3 (5)	3 (4)	29 (7)
3 rd graft	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	2 (1)
Overall adult elective⁴ (Chi-squared p-value=0.29)							
1 st graft	863 (91)	910 (92)	895 (91)	756 (92)	966 (93)	946 (93)	5336 (92)
2 nd graft	75 (8)	68 (7)	71 (7)	60 (7)	51 (5)	60 (6)	385 (7)
3 rd graft	9 (1)	12 (1)	12 (1)	9 (1)	18 (2)	10 (1)	70 (1)
4 th graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	9 (0)
6 th graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Total	951 (100)	990 (100)	980 (100)	826 (100)	1037 (100)	1017 (100)	5801 (100)

¹ One patient dual-listed was registered for a second graft in the twelve months prior whilst seven were registered for a first graft, two for a second graft, three for a third graft and one for a fourth graft in the sixty months post.

² Includes HCC downstaging all of whom were registered for first graft.

³ One patient dual-listed was registered for first graft and one for a second graft in the sixty months post.

⁴ Includes liver and cardiothoracic patients (all of whom were registered for first graft) and hepatoblastoma tier patients (all whom were registered for a first graft except for one registered for a third graft).

3.3.4. **Table 5** shows compares the median and interquartile age at registration for the twelve months pre and the sixty months post the introduction of NLOS for each type of adult patient registered over the last 72 months. There were no statistically significant differences in the median recipient age (Kruskal-Wallis p-value \geq 0.14).

Table 5	Median (IQR) age by time period for adult elective NHS Group 1 registrations in the UK, 20 March 2017 to 19 March 2023						
	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	Total
CLD¹ (Kruskal-Wallis p-value=0.23)							
N	674	721	739	637	787	746	4304
Median (IQR)	53 (44 - 61)	54 (44 - 61)	54 (45 - 61)	54 (44 - 60)	54 (43 - 60)	55 (44 - 61)	54 (44 - 61)
Range	17 - 76	17 - 73	17 - 74	17 - 71	17 - 74	17 - 71	17 - 76
HCC/HCC downstaging (Kruskal-Wallis p-value=0.49)							
N	193	195	178	147	167	170	1050
Median (IQR)	60 (55 - 65)	61 (56 - 65)	61 (55 - 66)	60 (56 - 64)	60 (56 - 66)	62 (57 - 65)	61 (56 - 65)
Range	20 - 75	21 - 73	21 - 72	19 - 73	43 - 73	37 - 72	19 - 75
Variant syndrome (Kruskal-Wallis p-value=0.79)							
N	83	71	56	38	63	83	394
Median (IQR)	49 (38 - 55)	51 (41 - 58)	48.5 (37.5 - 57.5)	48 (39 - 56)	48 (36 - 56)	48 (37 - 58)	48 (37 - 57)
Range	17 - 71	18 - 70	18 - 70	19 - 66	17 - 71	17 - 72	17 - 72
Overall adult elective² (Kruskal-Wallis p-value=0.15)							
N	951	990	980	826	1037	1017	5801
Median (IQR)	55 (46 - 62)	56 (47 - 62)	55 (47 - 62)	55 (45 - 61)	54 (45 - 61)	56 (46 - 62)	55 (46 - 62)
Range	17 - 76	17 - 73	17 - 74	17 - 73	17 - 74	17 - 72	17 - 76

¹ There was one patient dual-listed in the twelve months prior and 14 in the sixty months post

² Includes liver and cardiothoracic patients and hepatoblastoma tier/ACLF patients

3.4. POST-REGISTRATION OUTCOME

3.4.1. **Table 6** shows the one and three-month registration outcome for adult elective NHS Group 1 liver patients registered during the fifty-seven months since the implementation of the NLOS, 20 March 2018 -19 December 2022, along with the prior twelve-month period, 20 December 2016 – 19 December 2017. Note that the 2022/2023 period covers 9 months due to time to follow-up. There were 783 adult elective registrations in the 2022/2023 period post NLOS and 291 (37%) received a transplant within 3 months of registration. The corresponding three-month transplant rate for patients registered during the twelve months in 2016/2017 was 50%. There were statistically significant differences between the time periods and registration outcome at one month and three month (Chi-squared p-value<0.0001 for both).

3.4.2. **Table 6** also shows the six-month registration outcome for adult elective patients registered during the fifty-four months since the implementation of the NLOS, 20 March 2018 -19 September 2022, along with the prior twelve-month period, 20 September 2016 – 19 September 2017. There were statistically significant differences between the time periods and registration outcome at six months (Chi-squared p-value<0.0001). For the period 20 March 2022 to 19 September 2022, 240 (48%) of the 504 registrations were transplanted within 6 months compared with 62% in 2016/2017. The proportion of patients who either died on the list or were removed due to condition deterioration within six months was 7% compared with 8% in the 2016/2017 period prior.

Table 6 Registration outcome for adult elective NHS Group 1 registrations on the UK liver transplant list, 20 September 2016 to 19 December 2022

Registration outcome	2016/2017 ¹	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023 ²
One-month outcome (Chi-squared p-value<0.0001)						
Remained active/suspended	656 (69)	626 (63)	644 (66)	551 (67)	746 (72)	559 (71)
Died/ removed due to condition deterioration ³	21 (2)	14 (1)	10 (1)	20 (2)	17 (2)	21 (3)
Removed due to other reasons	5 (1)	10 (1)	10 (1)	33 (4)	19 (2)	12 (2)
Transplanted	263 (28)	337 (34)	314 (32)	222 (27)	255 (25)	191 (24)
Total	945 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	783 (100)
Three-month outcome (Chi-squared p-value<0.0001)						
Remained active/suspended	409 (43)	419 (42)	455 (47)	413 (50)	573 (55)	440 (56)
Died/ removed due to condition deterioration ³	55 (6)	32 (3)	27 (3)	39 (5)	35 (3)	35 (4)
Removed due to other reasons	13 (1)	18 (2)	18 (2)	41 (5)	23 (2)	17 (2)
Transplanted	468 (50)	518 (52)	478 (49)	333 (40)	406 (39)	291 (37)
Total	945 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	783 (100)
Six-month outcome (Chi-squared p-value<0.0001)						
Remained active/suspended	241 (27)	275 (28)	316 (32)	279 (34)	419 (40)	214 (42)
Died/ removed due to condition deterioration ³	68 (8)	44 (4)	48 (5)	72 (9)	62 (6)	36 (7)
Removed due to other reasons	31 (3)	29 (3)	24 (2)	57 (7)	30 (3)	14 (3)
Transplanted	566 (62)	639 (65)	590 (60)	418 (51)	526 (51)	240 (48)
Total	906 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	504 (100)
One-year outcome (Chi-squared p-value<0.0001)						
Remained active/suspended	132 (14)	153 (16)	184 (19)	163 (20)	281 (27)	
Died/ removed due to condition deterioration ³	101 (11)	64 (6)	76 (8)	92 (11)	89 (9)	
Removed due to other reasons	38 (4)	42 (4)	36 (4)	76 (9)	56 (5)	
Transplanted	653 (71)	728 (74)	682 (70)	495 (60)	611 (59)	
Total	924 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	


¹20 December 2016 to 19 December 2017 for one and three-month outcomes, 20 September 2016 to 19 September 2017 for six-month outcome and 20 March 2016 to 20 March 2017 for one-year outcome

²20 March 2022 to 19 December 2022 for one and three-month outcomes and 20 March 2022 to 19 September 2022 for six-month outcome


³ Includes patients removed as registered onto super-urgent list

3.4.3. **Figure 3** shows the three-month registration outcome by quarter and type of adult elective patient. HCC downstaging registrations are included with HCC registrations. The proportion of CLD patients registered post NLOS and transplanted in the first three months post-registration ranged between 37 and 63% compared with 46 and 55% of registrations in the year prior. There was a statistically significant association between three-month transplant rate and time period of registration for CLD patients, HCC/HCC downstaging patients and variant syndrome patients (Chi-squared p-value<0.05).


3.4.4. Equivalent charts for six-month and one-year are presented in **Figure B1** and **Figure C1** in **Appendix B** and **Appendix C** and show consistent results with the three-month outcome charts.




3.4.5. **Figure 4** shows the three-month registration outcome by quarter and age group. There was a statistically significant association (Chi-squared p-value<0.01) between transplant rate and time period of registration for all age groups except for 17-29 years. Equivalent charts for six-month and one-year are presented in **Figure B2** and **Figure C2** in **Appendix B** and **Appendix C** and show consistent results with the three-month outcome charts.




3.4.6. **Figure 5** shows the three-month registration outcome by quarter and whether the patient was registered for a first graft or re-graft. The proportion of first graft patients registered post NLOS and transplanted in the first three months post-registration ranges between 35 and 60% compared with 46 and 53% of registrations in the year prior. The proportion of re-graft patients registered post NLOS and transplanted in the first three months post-registration ranged between 14 and 50% compared with 25 and 53% of registrations in the year prior. There was a statistically significant association between transplant rate and time period of registration for patients registered for a first graft but not for re-graft patients (Chi-squared p-value <0.01 and 0.71 respectively). Equivalent charts for six-month and one-year are presented in **Figure B3** and **Figure C3** in **Appendix B** and **Appendix C** and show consistent results with the three-month outcome chart.



3.4.7. **Figure 6** shows the three-month registration outcome by quarter and sex. There was a statistically significant association between transplant rate and time period of registration for male and female patients (Chi-squared p-value <0.01). Equivalent charts for six-month and one-year are presented in **Figure B4** and **Figure C4** in **Appendix B** and **Appendix C** and show consistent results with the three-month outcome chart.



3.4.8. **Figure 7** shows the three-month registration outcome by quarter. The mortality rate in the first three months ranged between 2% and 8% in the quarters since the introduction of NLOS compared with between 4% and 7% in the quarters prior. Equivalent charts for six-month and one-year are presented in **Figure B5** and **Figure C5** in **Appendix B** and **Appendix C**.



3.4.9. Sixty-three patients listed for a regrant, either on the list on 20 March 2018 or registered during the sixty months post NLOS, were removed from the transplant list (regardless of reason). **Table 7** shows the other reasons for removal from the transplant list for each of the 63 patients.

Table 7 Reasons for removal for 63 regrant patients removed from the transplant list						
Patient number	Centre	Month removed	Time from previous tx	Time on the list	Reason for removal	Other reasons given
1	6	March 2018	1940	2562	Condition deteriorated	Deterioration of Hocum therefore not fit for OLTX
2	6	April 2018	1245	2	Other	At patient's request
3	5	May 2018	527	212	Condition deteriorated	
4	5	May 2018	1178	266	Condition improved	
5	6	July 2018	1106	247	Condition improved	
6	5	August 2018	480	596	Condition deteriorated	Awaiting cardiology review, episode of SVT yesterday
7	6	September 2018	1220	55	Condition deteriorated	Patient has developed lung cancer
8	6	December 2018	2799	24	Condition deteriorated	Has extra hepatic collections, needs addressing
9	3	February 2019	1903	337	Condition deteriorated	Further investigations required for anaemia and cardiac function
10	4	March 2019	2220	392	Condition improved	
11	5	April 2019	2736	6	Condition deteriorated	Patient has deteriorated and is no longer a transplant candidate.
12	6	June 2019	2564	74	Condition improved	
13	3	September 2019	158	150	Condition deteriorated	HCC in nodes outside liver
14	5	October 2019	3351	66	Condition deteriorated	Patient has developed multi-organ failure, rising lactate in the context of sepsis.
15	6	November 2019	5275	879	Condition deteriorated	Pt requires full assessment for retransplant now, after a long period of suspension on the waiting list since Aug 2018. Deemed medically too high risk to receive a transplant
16	3	December 2019	49	13	Condition improved	Clinically improving. No longer has an indication for transplant
17	7	January 2020	179	117	Condition Deteriorated	HCC metastases
18	5	February 2020	7655	164	Condition Deteriorated	super urgent request sent through via National appeal.
19	5	February 2020	808	604	Condition deteriorated	Requires Haematology review and bone marrow biopsy due to neutropenia
20	4	February 2020	103	30	Condition improved	OPA 13.2.20
21	3	February 2020	645	93	Condition improved	
22	1	March 2020	6929	10	Condition deteriorated	
23	5	July 2020	2907	609	Condition deteriorated	
24	6	July 2020	5537	764	Other	Patient now for palliative care in their local hospital
25	3	September 2020	56	1	Condition improved	Not clinically urgent
26	5	March 2021	11009	927	Condition deteriorated	Awaiting Vascular review, lower limb numbness and pain, known SMV calcification
27	2	April 2021	62	15	Other	Moved to su waiting list
28	6	April 2021	710	3	Condition improved	Request made by Hepatologist to Suspend as improved
29	6	May 2021	5498	74	Condition deteriorated	
30	7	May 2021	10069	654	Condition deteriorated	Patient pyrexial; patient died
31	4	May 2021	26	0	Registered onto the super-urgent list	
32	4	June 2021	545	381	Condition deteriorated	Admitted to ITU. Aim to get patient off ITU and to discharge with palliative care
33	5	June 2021	6249	84	Condition improved	Clinical condition improved since listing
34	6	August 2021	128	11	Condition deteriorated	Patient went for transplant found to have malignancy therefore abandoned

35	6	October 2021	198	739	Condition improved	
36	7	October 2021	168	103	Condition deteriorated	Patient too sick for liver transplant
37	2	October 2021	468	82	Patient/non-compliant	Following MDT - majority of the team do not support transplant due to concerns with compliance
38	5	October 2021	320	90	Condition deteriorated	
39	5	November 2021	1642	62	Condition deteriorated	Deteriorated and patient not keen on transplant
40	3	November 2021	1617	6	Condition deteriorated	
41	5	November 2021	1866	1256	Condition deteriorated	New PLTD diagnosis
42	2	November 2021	6606	42	Condition improved	Patient transferred and under assessment at new centre
43	6	December 2021	2649	457	Other	Drinking alcohol whilst on the waiting list
44	1	December 2021	53	4	Condition deteriorated	
45	6	January 2022	876	113	Condition improved	
46	6	March 2022	5352	32	Condition deteriorated	End of life care. Frailty. Refractory leg abscess. MOF.
47	2	April 2022	1463	185	Patient/non-compliant	
48	6	April 2022	1404	241	Condition improved	
49	4	May 2022	245	283	Condition improved	No indication for transplant-improved
50	5	June 2022	5910	698	Condition deteriorated	
51	3	July 2022	5802	65	Condition improved	
52	4	September 2022	513	448	Patient/non-compliant	Drinking alcohol whilst on the waiting list.
53	1	October 2022	271	58	Condition deteriorated	
54	6	October 2022	1014	396	Other	Dwindling indication
55	3	November 2022	3707	481	Condition deteriorated	
56	5	November 2022	9577	481	Patient/non-compliant	
57	1	December 2022	47	156	Condition improved	No longer meets listing criteria
58	5	January 2023	6133	1069	Condition deteriorated	
59	6	January 2023	1620	187	Condition improved	
60	6	February 2023	661	40	Condition improved	
61	6	February 2023	2297	30	Condition improved	
62	6	February 2023	748	540	Condition improved	
63	2	March 2023	1585	76	Patient/Non-compliant	Non-compliant

3.5. LIVER OFFERING

- 3.5.1. **Table 8** shows the overall UK deceased donor liver offering outcome between 20 March 2017 and 19 March 2023, by donor type and time period. 4367 DBD and 4353 DCD livers were offered for transplantation in the first sixty months of the scheme. Of the DBD livers offered, 3810 (87%) were retrieved for the purposes of transplantation and 3294 (86%) were transplanted (all but 22 were transplanted in the UK). The proportion of DBD livers offered and retrieved is very similar to the percentage for the 12 months prior to the introduction of the new scheme. **Table 8** also shows the liver offering outcome for donors where at least one solid organ was retrieved for the purposes of transplantation.
- 3.5.2. **Table 9A, 9B and 9C** shows, separately, the reasons for not offering, not retrieving and not transplanting livers by donor type and time period. The number in brackets are the corresponding values for solid organ donors where at least one organ was retrieved for the purposes of transplantation.

Table 8 Overall deceased donor liver offering outcome, 20 March 2017 to 19 March 2023, as at 27 April 2023

	DBD						DCD					
	17/18	18/19	19/20	20/21	21/22	22/23	17/18	18/19	19/20	20/21	21/22	22/23*
1. ALL DONORS												
Number donors	1067	1072	1070	875	883	831	1164	1224	1275	717	1032	1057
Liver not offered for donation	105 (10)	72 (7)	69 (6)	84 (10)	80 (9)	59 (7)	212 (18)	225 (18)	237 (19)	140 (20)	187 (18)	163 (15)
Liver offered for donation	962 (90)	1000 (93)	1001 (94)	791 (90)	803 (91)	772 (93)	952 (82)	999 (82)	1038 (81)	577 (80)	845 (82)	894 (85)
Liver not retrieved (% offered)	118 (12)	143 (14)	134 (13)	117 (15)	88 (11)	75 (10)	652 (68)	741 (74)	751 (72)	407 (71)	533 (63)	528 (59)
Liver retrieved (% offered)	844 (88)	857 (86)	867 (87)	674 (85)	715 (89)	697 (90)	300 (32)	258 (26)	287 (28)	170 (29)	312 (37)	366 (41)
Livers transplanted overseas (% retrieved)	4 (0)	9 (1)	3 (0)	2 (0)	6 (1)	2 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Livers transplanted in the UK (% retrieved)	765 (91)	754 (88)	735 (85)	580 (86)	604 (84)	599 (86)	198 (66)	191 (74)	176 (61)	114 (67)	195 (63)	243 (66)
Liver not transplanted (% retrieved)	75 (9)	94 (11)	129 (15)	92 (14)	105 (15)	96 (14)	102 (34)	67 (26)	111 (39)	56 (33)	117 (38)	123 (34)
Liver used for research (% not transplanted)	44 (59)	52 (55)	68 (53)	5 (5)	10 (10)	6 (6)	63 (62)	39 (58)	62 (56)	5 (9)	8 (7)	6 (5)
2. SOLID ORGAN DONORS												
Number donors	949	965	965	752	790	771	616	643	655	388	622	651
Liver not offered for donation	45 (5)	28 (3)	23 (2)	23 (3)	27 (3)	24 (3)	44 (7)	51 (8)	41 (6)	31 (8)	51 (8)	40 (6)
Liver offered for donation	904 (95)	937 (97)	942 (98)	729 (97)	763 (97)	747 (97)	572 (93)	592 (92)	614 (94)	357 (92)	571 (92)	611 (94)
Liver not retrieved (% offered)	60 (7)	80 (9)	75 (8)	55 (8)	48 (6)	50 (7)	272 (48)	334 (56)	327 (53)	187 (52)	259 (45)	245 (40)
Liver retrieved (% offered)	844 (93)	857 (91)	867 (92)	674 (92)	715 (94)	697 (93)	300 (52)	258 (44)	287 (47)	170 (48)	312 (55)	366 (60)
Livers transplanted overseas (% retrieved)	4 (0)	9 (1)	3 (0)	2 (0)	6 (1)	2 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Livers transplanted in the UK (% retrieved)	765 (91)	754 (88)	735 (85)	580 (86)	604 (84)	599 (86)	198 (66)	191 (74)	176 (61)	114 (67)	195 (63)	243 (66)
Liver not transplanted (% retrieved)	75 (9)	94 (11)	129 (15)	92 (14)	105 (15)	96 (14)	102 (34)	67 (26)	111 (39)	56 (33)	117 (38)	123 (34)
Liver used for research (% not transplanted)	44 (59)	52 (55)	68 (53)	5 (5)	10 (10)	6 (6)	63 (62)	39 (58)	62 (56)	5 (9)	8 (7)	6 (5)

**Table 9A Reasons for non-offering of livers from deceased donors (solid organ donors),
20 March 2017 to 19 March 2023, as at 27 April 2023**

	DBD						DCD					
	17/18	18/19	19/20	20/21	21/22	22/23	17/18	18/19	19/20	20/21	21/22	22/23
REASONS NOT OFFERED												
Family permission not sought	1 (1)	0 (0)	0 (0)	1 (1)	2 (2)	1 (0)	2 (2)	2 (2)	1 (1)	0 (0)	1 (0)	2 (1)
Family permission refused	20 (11)	10 (3)	8 (5)	3 (3)	7 (3)	2 (2)	26 (6)	18 (6)	3 (1)	9 (2)	9 (4)	14 (3)
Permission refused by coroner	18 (9)	7 (4)	0 (0)	5 (3)	7 (4)	6 (4)	5 (0)	9 (5)	10 (3)	4 (3)	8 (4)	6 (3)
Donor unsuitable - age	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	8 (4)	5 (2)	10 (6)	26 (11)	7 (5)	5 (3)
Donor unsuitable - past history	30 (20)	17 (14)	21 (16)	19 (13)	18 (15)	14 (14)	51 (23)	54 (27)	48 (18)	27 (12)	52 (29)	39 (23)
Donor unstable	1 (0)	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	4 (1)	1 (1)	2 (0)	0 (0)	0 (0)	0 (0)
Donor unsuitable - size	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	3 (3)
Donor arrested	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)
Centre already retrieving/transplanting	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Poor function	1 (0)	7 (6)	2 (2)	2 (2)	3 (2)	1 (1)	13 (5)	16 (7)	12 (6)	2 (1)	10 (6)	5 (4)
Infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (0)	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Other disease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Ischaemia time too long - warm	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Donor unsuitable - virology	4 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	8 (1)	2 (1)	3 (0)	7 (1)	2 (1)	3 (3)	26 (2)	18 (0)	26 (4)	7 (1)	12 (2)	6 (0)
Not reported	21 (1)	28 (0)	35 (0)	46 (0)	41 (0)	32 (0)	72 (1)	98 (0)	122 (0)	65 (1)	87 (0)	81 (0)
Total not offered	105 (45)	72 (28)	69 (23)	84 (23)	80 (27)	59 (24)	212 (44)	225 (51)	237 (41)	140 (31)	187 (51)	163 (40)

Table 9B Reasons for non-retrieval of livers from deceased donors (solid organ donors), 20 March 2017 to 19 March 2023, as at 27 April 2023

REASONS FOR NON-RETRIEVAL	DBD						DCD					
	17/18	18/19	19/20	20/21	21/22	22/23	17/18	18/19	19/20	20/21	21/22	22/23
Donor unsuitable - cod	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	1 (1)	0 (0)
Donor unsuitable - age	5 (3)	5 (4)	2 (2)	1 (.)	2 (.)	1 (.)	142 (55)	198 (93)	181 (82)	59 (28)	133 (65)	113 (64)
Donor unsuitable - past history	44 (21)	49 (25)	48 (28)	50 (30)	40 (21)	26 (19)	141 (75)	186 (99)	176 (89)	117 (64)	154 (91)	143 (83)
Donor recovered	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)	0 (0)	0 (0)
Donor unstable	2 (.)	2 (1)	0 (0)	0 (0)	0 (0)	1 (.)	2 (.)	3 (.)	0 (0)	0 (0)	1 (.)	5 (.)
Donor unsuitable - size	1 (.)	9 (4)	3 (3)	2 (.)	3 (3)	1 (1)	17 (12)	21 (15)	26 (18)	13 (8)	15 (9)	17 (14)
Donor arrested	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)	0 (0)	1 (.)	2 (.)
No suitable recipients	6 (4)	8 (4)	10 (5)	4 (2)	7 (3)	6 (6)	26 (14)	30 (18)	41 (18)	27 (16)	24 (15)	14 (8)
No time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)
Centre already retrieving/transplanting	1 (1)	0 (0)	0 (0)	2 (.)	0 (0)	1 (.)	1 (1)	0 (0)	8 (5)	5 (2)	3 (1)	7 (4)
Poor function	17 (11)	16 (12)	16 (9)	16 (8)	7 (6)	6 (3)	49 (32)	49 (32)	51 (31)	30 (17)	32 (24)	28 (15)
Infection	0 (0)	3 (.)	1 (.)	1 (.)	0 (0)	1 (.)	2 (.)	3 (3)	0 (0)	0 (0)	1 (1)	0 (0)
Tumour	2 (.)	0 (0)	3 (.)	1 (.)	2 (.)	1 (.)	1 (.)	0 (0)	1 (.)	1 (.)	0 (0)	0 (0)
Anatomy	0 (0)	0 (0)	1 (1)	2 (1)	4 (3)	4 (4)	0 (0)	0 (0)	1 (1)	0 (0)	4 (4)	2 (2)
Poor perfusion	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)
Other disease	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	1 (.)	0 (0)	0 (0)	0 (0)	0 (0)
HLA/ABO type	2 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	1 (1)	2 (1)	1 (1)	2 (2)	1 (1)	3 (3)
Ischaemia time too long - warm	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	2 (.)	13 (10)	22 (9)	32 (12)
Ischaemia time too long - cold	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)	3 (3)	4 (3)	1 (.)
No beds	0 (0)	0 (0)	1 (1)	1 (.)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (.)	5 (3)	0 (0)
Transport difficulties	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (.)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
No response to fast track offer	1 (1)	2 (2)	1 (1)	1 (.)	1 (1)	0 (0)	11 (2)	4 (1)	6 (4)	11 (5)	3 (2)	1 (.)
Fatty organ	10 (8)	14 (12)	12 (10)	7 (5)	7 (7)	10 (8)	12 (10)	7 (7)	9 (6)	1 (1)	2 (2)	11 (10)
Donor unsuitable - virology	9 (.)	7 (1)	13 (3)	1 (.)	1 (.)	3 (1)	8 (.)	10 (.)	13 (3)	4 (1)	6 (1)	0 (0)
Organ unsuitable for transplant	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	3 (1)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)
Other	17 (8)	27 (14)	21 (10)	22 (4)	12 (2)	11 (7)	237 (69)	222 (64)	234 (69)	117 (28)	117 (24)	146 (28)
Organ fibrotic	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)
TOTAL	118 (60)	143 (80)	134 (75)	117 (55)	88 (48)	75 (50)	652 (272)	741 (334)	751 (327)	407 (187)	533 (259)	528 (245)


**Table 9C Reasons for retrieving but not transplanting livers from deceased donors (solid organ donors),
20 March 2017 to 19 March 2023, as at 27 April 2023**


REASONS RETRIEVED BUT NOT TRANSPLANTED	DBD						DCD					
	17/18	18/19	19/20	20/21	21/22	22/23	17/18	18/19	19/20	20/21	21/22	22/23
Donor unsuitable - age	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	6 (6)
Donor unsuitable - past history	0 (0)	0 (0)	1 (1)	6 (6)	3 (3)	5 (5)	0 (0)	1 (1)	2 (2)	2 (2)	4 (4)	0 (0)
Donor unsuitable - size	1 (1)	0 (0)	1 (1)	1 (1)	8 (8)	3 (3)	0 (0)	1 (1)	1 (1)	3 (3)	5 (5)	4 (4)
No suitable recipients	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Poor function	0 (0)	1 (1)	1 (1)	4 (4)	10 (10)	9 (9)	0 (0)	0 (0)	1 (1)	5 (5)	15 (15)	19 (19)
Infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Tumour	3 (3)	0 (0)	2 (2)	0 (0)	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Anatomy	3 (3)	4 (4)	3 (3)	10 (10)	20 (20)	9 (9)	1 (1)	0 (0)	5 (5)	6 (6)	10 (10)	11 (11)
Poor perfusion	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	2 (2)	2 (2)	2 (2)	2 (2)	1 (1)	2 (2)	1 (1)
HLA/ABO type	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Organ damaged	0 (0)	0 (0)	3 (3)	4 (4)	3 (3)	2 (2)	1 (1)	0 (0)	3 (3)	2 (2)	3 (3)	6 (6)
Ischaemia time too long - warm	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (4)	3 (3)	3 (3)	4 (4)	6 (6)	3 (3)
Ischaemia time too long - cold	4 (4)	4 (4)	3 (3)	5 (5)	4 (4)	1 (1)	3 (3)	6 (6)	4 (4)	2 (2)	7 (7)	5 (5)
Recipient unfit	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Recipient died	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Recipient refused	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Used for hepatocytes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	1 (1)	1 (1)
No response to fast track offer	3 (3)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Used for research after declined by centres	42 (42)	49 (49)	64 (64)	5 (5)	5 (5)	5 (5)	60 (60)	36 (36)	57 (57)	5 (5)	7 (7)	2 (2)
Fatty organ	8 (8)	14 (14)	16 (16)	30 (30)	30 (30)	30 (30)	7 (7)	5 (5)	5 (5)	4 (4)	22 (22)	33 (33)
Organ unsuitable for transplant	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Other	11 (11)	19 (19)	32 (32)	24 (24)	18 (18)	23 (23)	22 (22)	12 (12)	25 (25)	18 (18)	32 (32)	28 (28)
Organ fibrotic	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
TOTAL	75 (75)	94 (94)	129 (129)	92 (92)	105 (105)	96 (96)	102 (102)	67 (67)	111 (111)	56 (56)	117 (117)	123 (123)

3.5.3. **Figure 8** shows the DBD liver offering outcome for all livers offered regardless of whether any solid organs were retrieved for the purposes of transplantation. **Figure 8** shows that 276 livers were offered during the first quarter of NLOS which was the second highest number of livers offered during the 72 month period.

3.5.4. The percentage of organs retrieved and transplanted per quarter ranged from 77% to 82% in the year prior and 67% to 82% in the sixty months post the introduction of NLOS. The percentage of livers retrieved and used for research ranged between 3% and 6% in the year prior and 0% to 10% for the sixty months post the introduction of NLOS.

3.5.5. **Figure 8A** shows the equivalent information for all solid organ donors where the liver was offered for transplantation and at least one organ (not necessarily the liver) was retrieved for the purposes of transplantation.





- 3.5.6. **Figure 9a** show the number of livers offered during the first sixty months of the new scheme at each stage of the liver offering pathway up to and including the liver and cardiothoracic section. Livers offered during COVID are included in **Figure 9a** but excluded at the elective stage of **Figure 9b**. 38 of the 4367 donors did not meet the DBD criteria at the start of the offering process and 33 were retrieved and transplanted. These livers are hence excluded from the offering pathway.
- 3.5.7. Livers from 509 donors meeting the DBD criteria were accepted and transplanted into super-urgent patients (including 20 super-urgent patients in Dublin). 661 livers were offered to hepatoblastoma/prioritised paediatric/ACLF patients and 49 were accepted and transplanted. 429 livers were offered to the liver and intestinal list and 43 were accepted and transplanted. Please note that a liver accepted and used at any stage may have been provisionally offered on to elective patients or fast-tracked before being accepted and used. These have not been included in the number of livers offered in later stages along with livers that may have been accepted, split and transplanted into two patients.
- 3.5.8. 898 livers were offered to liver and cardiothoracic patients and nine were accepted and transplanted combined liver and cardiothoracic patients. It should be noted that offers may be made when the cardiothoracic organs are unavailable.

- 3.5.9. **Figure 9b** shows the number of livers that were offered to elective patients and hadn't been accepted and used for super-urgent, hepatoblastoma, liver/intestinal and liver/cardiothoracic patients. Of the 3714 livers offered to elective patients, 3662 were adult donors and 52 were paediatric donors (aged less than 16 years or weighing 40 kg or less). 667 adult donors met the split criteria and 596 livers were offered to paediatric centres for paediatric/small adult patients. 190 of the 596 livers were accepted and transplanted. Forty-two livers were only offered to paediatric patients and not offered to elective adult patient or fast-tracked.
- 3.5.10. 163 livers were offered to elective patients between 27 March and 9 July 2020.
- 3.5.11. Ninety percent of livers offered to elective patients were randomly allocated to the elective CLD/HCC pathway while ten percent were allocated to the variant syndrome pathway. Of the 3159 livers allocated to the CLD/HCC pathway, 2819 (89%) were offered to named patients and 1696 (60%) were accepted and transplanted. Of the 350 livers allocated to the VS pathway, 287 (82%) were offered and 137 (48%) were accepted and transplanted.

Figure 9A Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 March 2023





Figure 9B Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 March 2023





3.5.12. **able 10** shows the number of liver offers made to each UK liver transplant centre in either the twelve months prior to the new scheme or during the first sixty months of the new scheme. Livers offered to intestinal or liver/cardiothoracic patients have been excluded. The number of offers made to UK liver transplant centres has increased compared with the 12 months prior.

Table 10 Number of DBD liver only offers (excludes intestinal and liver/cardiothoracic offers) per UK transplant centre, 20 March 2017 to 19 March 2023

	2017/18		2018/19		2019/20		2020/21		2021/22		2022/23	
	No. of offers (no. of donors)	Median (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor
A. All liver offers												
Newcastle	344 (323)	1 (1, 1)	431 (378)	1 (1, 1)	432 (386)	1 (1, 1)	402 (343)	1 (1, 1)	316 (286)	1 (1, 1)	272 (245)	1 (1, 1)
Leeds	501 (435)	1 (1, 1)	645 (481)	1 (1, 2)	733 (545)	1 (1, 2)	632 (443)	1 (1, 2)	611 (445)	1 (1, 2)	546 (416)	1 (1, 1)
Cambridge	348 (323)	1 (1, 1)	479 (391)	1 (1, 1)	455 (386)	1 (1, 1)	434 (352)	1 (1, 1)	401 (348)	1 (1, 1)	369 (315)	1 (1, 1)
Royal Free	384 (352)	1 (1, 1)	566 (459)	1 (1, 1)	489 (420)	1 (1, 1)	463 (368)	1 (1, 1)	480 (376)	1 (1, 1)	386 (306)	1 (1, 1)
Kings College	516 (455)	1 (1, 1)	1018 (638)	1 (1, 2)	901 (629)	1 (1, 2)	808 (531)	1 (1, 2)	920 (565)	1 (1, 2)	815 (505)	1 (1, 2)
Birmingham	495 (417)	1 (1, 1)	867 (582)	1 (1, 2)	829 (591)	1 (1, 2)	673 (468)	1 (1, 2)	730 (488)	1 (1, 2)	648 (437)	1 (1, 2)
Edinburgh	374 (351)	1 (1, 1)	511 (426)	1 (1, 1)	470 (415)	1 (1, 1)	509 (395)	1 (1, 1)	407 (346)	1 (1, 1)	358 (312)	1 (1, 1)
Total	2962 (944)	2 (1, 5)	4517 (982)	3 (2, 7)	4309 (986)	3 (1, 7)	3921 (777)	4 (1, 8)	3865 (786)	4 (1, 8)	3394 (765)	3 (1, 7)
B. All liver offers for livers ultimately transplanted												
Newcastle	174 (161)	1 (1, 1)	211 (192)	1 (1, 1)	208 (184)	1 (1, 1)	205 (176)	1 (1, 1)	157 (139)	1 (1, 1)	130 (118)	1 (1, 1)
Leeds	324 (277)	1 (1, 1)	367 (276)	1 (1, 2)	429 (320)	1 (1, 2)	376 (263)	1 (1, 2)	376 (273)	1 (1, 2)	354 (273)	1 (1, 1)
Cambridge	191 (173)	1 (1, 1)	263 (221)	1 (1, 1)	240 (203)	1 (1, 1)	231 (188)	1 (1, 1)	205 (182)	1 (1, 1)	216 (182)	1 (1, 1)
Royal Free	209 (193)	1 (1, 1)	320 (263)	1 (1, 1)	237 (199)	1 (1, 1)	250 (196)	1 (1, 1)	265 (208)	1 (1, 1)	211 (169)	1 (1, 1)
Kings College	327 (287)	1 (1, 1)	654 (421)	1 (1, 2)	546 (397)	1 (1, 2)	511 (343)	1 (1, 2)	607 (386)	1 (1, 2)	565 (353)	1 (1, 2)
Birmingham	313 (261)	1 (1, 1)	539 (379)	1 (1, 2)	507 (368)	1 (1, 2)	409 (294)	1 (1, 2)	476 (318)	1 (1, 2)	398 (287)	1 (1, 1)
Edinburgh	209 (192)	1 (1, 1)	273 (231)	1 (1, 1)	221 (192)	1 (1, 1)	283 (217)	1 (1, 1)	211 (177)	1 (1, 1)	201 (171)	1 (1, 1)
Total	1747 (755)	1 (1, 3)	2627 (748)	2 (1, 5)	2388 (726)	2 (1, 5)	2265 (575)	3 (1, 6)	2297 (595)	3 (1, 6)	2075 (595)	2 (1, 5)

3.5.13. **Figure 10** shows, for livers that were ultimately transplanted, the outcome of liver offers made in either the last year prior to the new scheme or during the first sixty months of the new scheme. The last time period has been split as the parameter estimates and baseline survivor functions were updated on 4 October 2022. Fast-track offers that were not accepted and transplanted (i.e. declined or accepted and not used fast-track offers) as well as livers offered from either DCD or positive virology donors were excluded. It should be noted that offers of left and right lobes are included. The proportion of offers accepted and not used has increased compared with the 12 months prior. **Figure 10A** shows the equivalent for each transplant centre.



- 3.5.14. 7038 (35%) of the 20006 offers made in the first 60 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 4895 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.5.15. The number of named patient offers per donor ranged between 1 and 18 with a median of two named patient offers per donor. The number of named offers per patient ranged between 1 and 27 with a median of two offers per patient. Forty four patients at 7 centres were offered 11 or more livers in the sixty month time period (15 were offered 11 livers, 9 were offered 12 livers, 5 were offered 13 livers, 6 were offered 14 livers, 1 was offered 15 livers, 2 were offered 17, 1 was offered 18 livers, 1 was offered 19 livers, 1 was offered 21 and 3 were offered 27 livers).
- 3.5.16. **Table 11** shows the outcome of named patient liver offers made during the first sixty months of the new scheme by type of patient. It also shows the offer outcome after excluding named patients offers for livers that were ultimately not transplanted. Overall, forty-five percent of named patient offers were accepted and 26% were accepted and transplanted. The number of transplants will not agree with the flow chart in **Figure 9A** as **Table 11** includes all elective named patient offers and will include livers that were offered as a right lobe after being accepted for super-urgent and hepatoblastoma patients.
- 3.5.17. **Figures 11A, 11B** and **11C** shows the outcome of named CLD patient liver offers made during the first sixty months of the new scheme for livers ultimately transplanted by aetiology, transplant centre and blood group respectively. There were statistically significant differences at a 5% significance level in the outcomes for patients with ALD ($p=0.03$), PSC ($p=0.05$) and AID ($p=0.02$).
- 3.5.18. **Figures 12A** and **12B** for shows the outcome of named HCC patient liver offers made during the first fifty-four months of the new scheme for livers ultimately transplanted by transplant centre and blood group respectively. **Figures 13A** and **13B** show equivalent information for variant syndrome patients.

Table 11 Offer outcome for named elective patient offers made between 20 March 2018 and 19 March 2023 (excluding 27 March 2020 to 9 July 2020), by type of patient

Type of patient	Disease group	Offer outcome for all named patient offers				Offer outcome for all named patient offers for livers that were ultimately transplanted			
		Declined	Accepted but not used	Transplanted	Total	Declined	Accepted but not used	Transplanted	Total
Chronic Liver Disease (CLD)	2018/2019	789 (55)	246 (17)	409 (28)	1444	491 (47)	142 (14)	409 (39)	1042
	2019/2020	613 (50)	250 (20)	361 (29)	1224	346 (42)	118 (14)	361 (44)	825
	2020/2021 ¹	544 (59)	162 (17)	223 (24)	929	315 (51)	78 (13)	223 (36)	616
	2021/2022	796 (58)	252 (18)	336 (24)	1384	493 (51)	131 (14)	336 (35)	960
	20 Mar – 3 Oct 22	290 (51)	110 (19)	169 (30)	569	202 (47)	57 (13)	169 (39)	428
	4 Oct 22 – 19 Mar 23	203 (48)	89 (21)	133 (31)	425	103 (37)	43 (15)	133 (48)	279
	Total	3235 (54)	1109 (19)	1631 (27)	5975	1950 (47)	569 (14)	1631 (39)	4150
HCC	2018/2019	31 (53)	12 (20)	16 (27)	59	24 (53)	5 (11)	16 (36)	45
	2019/2020	29 (44)	12 (18)	25 (38)	66	11 (24)	9 (20)	25 (56)	45
	2020/2021 ¹	31 (57)	13 (24)	10 (19)	54	25 (61)	6 (15)	10 (24)	41
	2021/2022	39 (58)	11 (16)	17 (25)	67	17 (44)	5 (13)	17 (44)	39
	20 Mar – 3 Oct 22	27 (60)	8 (18)	10 (22)	45	22 (61)	4 (11)	10 (28)	36
	4 Oct 22 – 19 Mar 23	27 (44)	16 (26)	18 (30)	61	10 (31)	4 (13)	18 (56)	32
	Total	184 (52)	72 (20)	96 (27)	352	109 (46)	33 (14)	96 (40)	238
Variant syndrome	2018/2019	80 (56)	27 (19)	35 (25)	142	55 (53)	14 (13)	35 (34)	104
	2019/2020	92 (58)	28 (18)	39 (25)	159	66 (55)	16 (13)	39 (32)	121
	2020/2021 ¹	58 (64)	19 (21)	13 (14)	90	22 (50)	9 (20)	13 (30)	44
	2021/2022	132 (68)	38 (19)	25 (13)	195	94 (65)	26 (18)	25 (17)	145
	20 Mar – 3 Oct 22	49 (65)	13 (17)	13 (17)	75	30 (60)	7 (14)	13 (26)	50
	4 Oct 22 – 19 Mar 23	31 (62)	6 (12)	13 (26)	50	27 (63)	3 (7)	13 (30)	43
	Total	442 (62)	131 (19)	138 (19)	711	294 (58)	75 (15)	138 (27)	507
Total named patient offers		3861 (55)	1312 (19)	1865 (26)	7035	2353 (48)	677 (14)	1865 (38)	4895

¹ Offers between 27 March 2020 and 9 July excluded

Figure 11A Named CLD patient offer outcome, by year and disease group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2023 (excluding offers between 27 March and 9 July 2020)




Figure 11B Named CLD patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2023 (excluding offers between 27 March and 9 July 2020)




Figure 11C Named CLD patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2023 (excluding offers between 27 March and 9 July 2020)




Figure 12A Named HCC patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2023 (excluding offers between 27 March and 9 July 2020)










Figure 12B Named HCC patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2023 (excluding offers between 27 March and 9 July 2020)





3.5.19. **Figures 14A, 14B and 14C** show the median Transplant Benefit Score (TBS) at time of offer for named elective CLD patient offers for *livers ultimately transplanted* by, separately, aetiology, centre and blood group. Overall, the median TBS ranged between 1124 and 1233 days by year.






3.6. TRANSPLANT ACTIVITY

3.6.1. **Table 14** shows the urgency status and age group of DBD and DCD liver transplants performed in the UK between 20 March 2017 and 19 March 2023. The proportion of super-urgent transplants performed has increased from prior to NLOS implementation to 2022/23 (11% vs 14% respectively). There was evidence of a statistically significant difference for adult DBD liver and adult liver/kidney transplants (overall Chi-squared p-value=0.04) however there was not a significant difference for paediatric transplants (overall Chi-squared p-value=0.17). Highlighted in red are the transplants that will be analysed further in the rest of the section.

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)
DBD liver						
Adult elective liver and liver/kidney	640 (78.1)	623 (77.6)	608 (77.8)	477 (76.8)	481 (74.6)	449 (70.7)
Adult elective multivisceral	6 (0.7)	5 (0.6)	6 (0.8)	1 (0.2)	9 (1.4)	8 (1.3)
Adult elective liver/ cardiothoracic	2 (0.2)	0 (0)	2 (0.3)	3 (0.5)	3 (0.5)	1 (0.2)
Adult super-urgent liver and liver/kidney	94 (11.5)	100 (12.5)	83 (10.6)	61 (9.8)	75 (11.6)	96 (15.1)
Adult super-urgent multivisceral	1 (0.1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.2)
Paediatric elective liver and liver/kidney	57 (7.0)	55 (6.8)	64 (8.2)	63 (10.1)	53 (8.2)	53 (8.3)
Paediatric elective multivisceral	6 (0.7)	3 (0.4)	2 (0.3)	4 (0.6)	2 (0.3)	3 (0.5)
Paediatric super-urgent liver and liver/kidney	13 (1.6)	17 (2.1)	16 (2.0)	12 (1.9)	22 (3.4)	24 (3.8)
Total UK DBD transplants	819 (80.5)	803 (80.8)	781 (81.5)	621 (84.4)	645 (77.0)	635 (71.8)
DCD liver						
Adult elective liver and liver/kidney	190 (96.0)	185 (96.9)	173 (97.7)	110 (95.7)	189 (97.9)	243 (97.6)
Adult super-urgent liver and liver/kidney	1 (0.5)	1 (0.5)	3 (1.7)	2 (1.7)	2 (1.0)	1 (0.4)
Paediatric elective liver and liver/kidney	7 (3.5)	4 (2.1)	1 (0.6)	2 (1.7)	2 (1.0)	5 (2.0)
Paediatric super-urgent liver and liver/kidney	0 (0)	1 (0.5)	0 (0)	1 (0.9)	0 (0)	0 (0)
Total UK DCD transplants	198 (19.5)	191 (19.2)	177 (18.5)	115 (15.6)	193 (23.0)	249 (28.2)
Total UK transplants	1017 (100)	994 (100)	958 (100)	736 (100)	838 (100)	884 (100)

3.6.2. **Figure 15** shows the number of transplants over the time periods of interest, by transplant centre and donor type.

Figure 15 Number of deceased donor liver transplants performed in the UK by transplant centre and donor type, 20 March 2017 - 19 March 2023



3.6.3. One hundred and forty of the 3676 adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the rest of the section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients. Sixteen NHS group 2 transplants (1 performed at London Bridge and 15 performed at King's College) and three intestinal liver only transplants performed at Cambridge between August 2017 and September 2018 have been excluded from the rest of this section.

3.6.4. **Table 15** and **Table 16** show the demographics of adult elective liver and liver/kidney DBD and DCD transplants performed in the UK during the time periods of interest.

Table 15 Adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2023 as at 27 April 2023

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)
Total	635	621	607	476	481	449
Offer type						
Named patient		491 (79.1)	441 (72.7)	344 (72.3)	395 (82.1)	378 (84.2)
Fast-track		130 (20.9)	166 (27.3)	132 (27.7)	86 (17.9)	71 (15.8)
Rank on matching run						
Median (IQR)		2 (1 – 4)	2 (1 – 4)	2 (1 – 5)	2 (1 – 4)	2 (1 - 3)
(Range)		(1 - 187)	(1 – 191)	(1 – 204)	(1 – 362)	(1 - 415)
Transplant Benefit Score						
Median (IQR)		1131.98 (881 – 1301)	1096.12 (885 – 1289)	1090.12 (838 – 1281)	1155.10 (923 – 1314)	1170.78 (1014 – 1317)
(Range)		(-493 – 1617)	(-549 – 1616)	(-1535 - 1563)	(-289 – 1600)	(-215 – 1635)
Transplant Type						
Liver only	615 (96.9)	609 (97.9)	593 (97.7)	469 (98.5)	475 (98.8)	443 (98.7)
Liver & kidney	20 (3.1)	13 (2.1)	14 (2.3)	7 (1.5)	6 (1.2)	6 (1.3)
Type of Liver Transplanted						
Whole liver	596 (93.9)	581 (93.6)	569 (93.7)	443 (93.1)	447 (92.9)	419 (93.3)
Split liver	39 (6.1)	40 (6.4)	37 (6.1)	33 (6.9)	34 (7.1)	28 (6.2)
Reduced liver	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	2 (0.4)
Recipient Age Group						
17-25 years	27 (4.3)	37 (6.0)	35 (5.8)	34 (7.1)	25 (5.2)	22 (4.9)
26-39 years	95 (15.0)	68 (11.0)	64 (10.5)	41 (8.6)	49 (10.2)	47 (10.5)
40-49 years	98 (15.4)	75 (12.1)	68 (11.2)	78 (16.4)	85 (17.7)	53 (11.8)
50-59 years	208 (32.8)	202 (32.5)	213 (35.1)	170 (35.7)	133 (27.7)	131 (29.2)
60-69 years	193 (30.4)	231 (37.2)	212 (34.9)	144 (30.3)	174 (36.2)	187 (41.6)
70+ years	14 (2.2)	8 (1.3)	15 (2.5)	9 (1.9)	15 (3.1)	9 (2.0)
Recipient Sex						
Male	395 (62.2)	395 (63.6)	369 (60.8)	297 (62.4)	318 (66.1)	275 (61.2)
Female	240 (37.8)	226 (36.4)	238 (39.2)	179 (37.6)	163 (33.9)	174 (38.8)
Type of Patient						
CLD	477 (75.1)	485 (78.1)	471 (77.6)	398 (83.6)	401 (83.4)	362 (80.6)
HCC	104 (16.4)	72 (11.6)	80 (13.2)	54 (11.3)	39 (8.1)	45 (10.0)
VS	49 (7.7)	59 (9.5)	51 (8.4)	21 (4.4)	28 (5.8)	29 (6.5)
HCC downstaging	5 (0.8)	5 (0.8)	5 (0.8)	3 (0.6)	3 (0.6)	0 (0)
ACLF	0 (0)	0 (0)	0 (0)	0 (0)	10 (2.1)	13 (2.96)
Robert's Disease Group						
HCC	109 (17.2)	78 (12.5)	85 (14.0)	57 (12.0)	45 (9.4)	51 (11.4)
HCV	23 (3.6)	12 (1.9)	16 (2.6)	9 (1.9)	6 (1.2)	4 (0.9)
ALD	139 (21.9)	169 (27.2)	153 (25.2)	127 (26.7)	149 (31.0)	136 (30.3)
HBV	8 (1.3)	13 (2.1)	6 (1.0)	2 (0.4)	11 (2.3)	7 (1.6)
PSC	86 (13.5)	72 (11.6)	63 (10.4)	47 (9.9)	56 (11.6)	57 (12.7)
PBC	37 (5.8)	49 (7.9)	47 (7.7)	43 (9.0)	37 (7.7)	33 (7.3)
AID	44 (6.9)	51 (8.2)	48 (7.9)	38 (8.0)	38 (7.9)	26 (5.8)
NAFLD	67 (10.6)	72 (11.6)	71 (11.7)	54 (11.3)	68 (14.1)	69 (15.4)
Metabolic (excl. NAFLD)	8 (1.3)	13 (2.1)	23 (3.8)	7 (1.5)	9 (1.9)	9 (2.0)
Other	58 (9.1)	40 (6.4)	44 (7.2)	38 (8.0)	35 (7.3)	26 (5.8)
Retransplant	56 (8.8)	53 (8.5)	51 (8.4)	54 (11.3)	27 (5.6)	31 (6.9)

Table 15 Adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2023 as at 27 April 2023

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)
Total	635	621	607	476	481	449
Liver Transplant Number						
First liver transplant	579 (91.2)	567 (91.3)	556 (91.6)	421 (88.4)	454 (94.4)	418 (93.1)
Second	46 (7.2)	51 (8.2)	40 (6.6)	45 (9.5)	18 (3.7)	26 (5.8)
Third	7 (1.1)	3 (0.5)	8 (1.3)	9 (1.9)	8 (1.7)	4 (0.9)
Fourth	2 (0.3)	0 (0)	3 (0.5)	1 (0.2)	1 (0.2)	1 (0.2)
Sixth	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Blood Group Compatibility*						
Identical	628 (98.9)	607 (97.7)	574 (94.6)	451 (94.7)	460 (95.8)	426 (94.9)
Compatible	6 (0.9)	14 (2.3)	33 (5.4)	25 (5.3)	20 (4.2)	23 (5.1)
Incompatible	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Zonal Transplants						
Non zonal	167 (26.3)	487 (78.4)	486 (80.1)	398 (83.6)	389 (80.9)	360 (80.2)
Zonal	468 (73.7)	134 (21.6)	121 (19.9)	78 (16.4)	92 (19.1)	89 (19.8)
Blood group matching* (D=donor, R=recipient)						
DO, RO	297 (46.8)	294 (47.3)	262 (43.2)	182 (38.2)	171 (35.6)	156 (34.7)
DO, RA	1 (0.2)	0 (0)	3 (0.5)	5 (1.1)	8 (1.7)	7 (1.6)
DO, RB	1 (0.2)	1 (0.2)	5 (0.8)	5 (1.1)	5 (1.0)	6 (1.3)
DA, RO	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
DA, RA	245 (38.6)	236 (37.9)	235 (38.7)	203 (42.6)	213 (44.4)	217 (48.3)
DA, RAB	4 (0.6)	11 (1.8)	20 (3.3)	10 (2.1)	6 (1.3)	9 (2.0)
DB, RB	70 (11.0)	55 (8.8)	59 (9.7)	55 (11.6)	52 (10.8)	43 (9.6)
DB, RAB	0 (0)	2 (0.3)	5 (0.8)	5 (1.1)	1 (0.2)	1 (0.2)
DAB, RAB	16 (2.5)	23 (3.7)	18 (3.0)	11 (2.3)	24 (5.0)	10 (2.2)

* 1 transplant performed with unknown donor blood group in 2021/22

Table 16 Adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2023 as at 27 April 2023

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)
Total	186	182	170	110	189	243
Transplant Type						
Liver only	186 (100)	182 (100)	169 (99.4)	110 (100)	189 (100)	241 (99.2)
Liver & kidney	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	2 (0.8)
Type of Liver Transplanted						
Whole liver	186 (100)	182 (100)	170 (100)	110 (100)	189 (100)	243 (100)
Recipient Age Group						
17-25 years	4 (2.2)	5 (2.8)	5 (2.9)	1 (0.9)	1 (0.5)	5 (2.1)
26-39 years	10 (5.4)	17 (9.3)	16 (9.4)	14 (12.7)	19 (10.1)	30 (12.3)
40-49 years	24 (12.9)	23 (12.6)	25 (14.7)	17 (15.5)	35 (18.5)	39 (16.0)
50-59 years	76 (40.9)	73 (40.1)	55 (32.4)	36 (32.7)	83 (43.9)	82 (33.7)
60-69 years	66 (35.5)	58 (31.9)	68 (40.0)	39 (35.5)	48 (25.4)	82 (33.7)
70+ years	6 (3.2)	6 (3.3)	1 (0.6)	3 (2.7)	3 (1.6)	5 (2.1)
Recipient Sex						
Male	119 (64.0)	130 (71.4)	106 (62.4)	76 (69.1)	132 (69.8)	180 (74.1)
Female	67 (36.0)	52 (28.6)	64 (37.6)	34 (30.9)	57 (30.2)	63 (25.9)
Type of Patient						
CLD	123 (66.1)	87 (47.8)	107 (62.9)	72 (65.5)	104 (55.0)	145 (59.7)
HCC	52 (28.0)	83 (45.6)	58 (34.1)	33 (30.0)	73 (38.6)	84 (34.6)
VS	9 (4.8)	5 (2.7)	1 (0.6)	2 (1.8)	8 (4.2)	12 (4.9)
HCC downstaging	2 (1.1)	7 (3.8)	4 (2.4)	3 (2.7)	3 (1.6)	0 (0)
ACLF	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.5)	2 (0.8)
Robert's Disease Group						
HCC	55 (29.6)	91 (50.0)	62 (36.5)	36 (32.7)	76 (40.2)	88 (36.2)
HCV	4 (2.2)	3 (1.6)	3 (1.8)	2 (1.8)	6 (3.2)	3 (1.2)
ALD	43 (23.1)	35 (19.2)	43 (25.3)	20 (18.2)	41 (21.7)	57 (23.5)
HBV	3 (1.6)	1 (0.5)	2 (1.2)	1 (0.9)	3 (1.6)	6 (2.5)
PSC	19 (10.2)	12 (6.6)	17 (10)	16 (14.5)	15 (7.9)	29 (11.9)
PBC	24 (12.9)	7 (3.8)	18 (10.6)	9 (8.2)	10 (5.3)	14 (5.8)
AID	10 (5.4)	7 (3.8)	5 (2.9)	4 (3.6)	10 (5.3)	14 (5.8)
NAFLD	21 (11.3)	13 (7.1)	8 (4.7)	8 (7.3)	10 (5.3)	17 (7.0)
Metabolic (excluding NAFLD)	4 (2.2)	2 (1.1)	1 (0.6)	3 (2.7)	1 (0.5)	2 (0.8)
Other	0 (0)	6 (3.3)	8 (4.7)	4 (3.6)	11 (5.8)	9 (3.7)
Retransplant	3 (1.6)	5 (2.7)	3 (1.8)	7 (6.4)	6 (3.2)	4 (1.6)
Liver Transplant Number						
First liver transplant	183 (98.4)	177 (97.3)	167 (98.2)	103 (93.6)	183 (96.8)	239 (98.4)
Second	3 (1.6)	5 (2.7)	3 (1.8)	7 (6.4)	4 (2.1)	3 (1.2)
Third	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.1)	1 (0.4)
Blood Group Compatibility*						
Identical	185 (99.5)	175 (96.2)	161 (94.7)	109 (99.1)	182 (96.3)	234 (96.3)
Compatible	1 (0.5)	7 (3.8)	9 (5.3)	1 (0.9)	7 (3.7)	9 (3.7)
Incompatible	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Zonal Transplants						
Non zonal	65 (34.9)	75 (41.2)	65 (38.2)	42 (38.2)	77 (40.7)	86 (35.4)
Zonal	121 (65.1)	107 (58.8)	105 (61.8)	68 (61.8)	112 (59.3)	157 (64.6)

Table 16 Adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2023 as at 27 April 2023

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)
Total	186	182	170	110	189	243
Blood group matching* (D=donor, R=recipient)						
DO, RO	95 (51.1)	79 (43.4)	68 (40.0)	52 (47.3)	88 (46.6)	115 (47.3)
DO, RA	0 (0)	0 (0)	3 (1.8)	1 (0.9)	4 (2.1)	2 (0.8)
DO, RB	0 (0)	5 (2.7)	5 (2.9)	0 (0)	2 (1.1)	6 (2.5)
DA, RO	0 (0)	1 (0.5)	0 (0)	0 (0)	1 (0.5)	0 (0)
DA, RA	70 (37.6)	75 (41.2)	77 (45.3)	48 (43.6)	73 (38.6)	88 (36.2)
DA, RAB	1 (0.5)	1 (0.5)	0 (0)	0 (0)	0 (0)	1 (0.4)
DB, RB	18 (9.7)	16 (8.8)	13 (7.6)	7 (6.4)	21 (11.1)	27 (11.1)
DB, RAB	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	0 (0)
DAB, RAB	2 (1.1)	5 (2.7)	3 (1.8)	2 (1.8)	0 (0)	4 (1.6)

3.6.5. **Table 17** and **Table 18** shows the median waiting time to transplant for the adult elective transplants performed in the UK by transplant centre, blood group and type of patient, for DBD and DCD transplants respectfully. Overall, the median time to transplant was statistically significantly different across the time periods of interest for both DBD and DCD transplants (both with a Kruskal-Wallis p-value<0.0001).

Table 17 Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2023, as at 27 April 2023

	2017/18			2018/19			2019/20			2020/21			2021/22			LAG(23)03	2022/23	
	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range
Overall	635	71 (23 - 198)	0 -1835	622	39 (10 - 138)	1 -1711	607	43 (10 - 144)	0 -1620	476	43 (9 - 164.5)	0 -1814	481	33 (9 - 105)	0 - 1470	449	40 (9 - 156)	1 - 2223
Type of patient																		
CLD	477	65 (20 - 186)	0 -1519	485	30 (8 - 96)	1 -1518	471	25 (8 - 93)	0 - 1450	398	32 (8 - 150)	0 -1814	401	25 (8 - 82)	0 - 1470	362	28.5 (8 - 123)	1 - 2223
HCC	104	57 (23 - 184)	2 -1030	72	55 (22.5 - 145)	1 - 568	80	79 (33.5 - 167.5)	1 - 739	54	62 (24 - 128)	0 - 664	39	53 (21 - 107)	2 - 1400	45	77 (27 - 179)	1 - 769
VS	49	187 (79 - 543)	2 -1835	59	296 (100 - 836)	2 -1711	51	365 (174 - 613)	16 - 1620	21	367 (261 - 585)	3 -1260	28	385 (200 - 612)	17 - 1326	29	570 (264 - 879)	20 - 2099
ACLF	0	-	-	0	-	-	0	-	-	0	-	-	10	11.5 (5 - 42)	2 - 968	13	10 (7 - 63)	2 - 1014
HCC downstaging	5	93 (63 - 131)	16 -384	5	14 (10 - 27)	6 - 65	5	58 (22 - 128)	17 - 204	3	44 (4 - 240)	4 - 240	3	42 (31 - 115)	31 - 115	0	-	-
Centre																		
Newcastle	30	47 (17 - 111)	1 - 377	22	43 (17 - 96)	2 - 318	26	28.5 (14 - 85)	1 - 517	27	52 (20 - 190)	2 - 607	23	45 (13 - 110)	2 - 760	14	8.5 (5 - 45)	4 - 998
Leeds	108	64.5 (26 - 228.5)	1 -1402	66	41.5 (9 - 145)	1 -1341	79	33 (9 - 136)	1 - 1405	70	52.5 (14 - 159)	1 -1260	60	27.5 (9 - 113)	1 - 1187	74	22.5 (7 - 133)	1 - 1058
Cambridge	71	74 (21 - 200)	0 -1343	65	36 (10 - 88)	1 - 760	60	17 (8.5 - 67)	1 - 656	35	23 (9 - 76)	0 - 679	50	37 (9 - 90)	0 - 633	40	15 (7 - 62.5)	1 - 407
Royal Free	84	99.5 (29.5 - 236.5)	0 - 945	83	33 (7 - 133)	1 -1261	91	37 (11 - 96)	1 - 971	57	39 (8 - 95)	0 - 699	65	28 (8 - 154)	2 - 592	68	50 (11 - 241)	2 - 1453
Kings College Birmingham	128	125 (45 - 374)	1 -1813	143	54 (11 - 252)	1 -1711	145	54 (11 - 164)	1 - 1620	115	32 (8 - 140)	0 -1687	117	33 (9 - 98)	1 - 968	98	85.5 (11 - 288)	2 - 2099
Edinburgh	133	48 (15 - 137)	0 -1519	155	42.5 (11 - 105)	1 -1657	154	58.5 (9 - 204)	0 - 976	114	71.5 (8 - 262)	1 -1814	127	34 (9 - 146)	1 - 1470	115	65 (16 - 286)	1 - 2223
	81	42 (12 - 109)	0 -1835	88	24.5 (6 - 115.5)	1 -1124	52	46.5 (19 - 140)	2 - 640	58	45.5 (9 - 239)	1 - 749	39	17 (7 - 39)	1 - 452	40	22.5 (8 - 58)	2 - 218
Recipient blood group																		
O	298	113.5 (32-280)	0 -1835	294	60 (14 - 218)	1 -1711	262	56.5 (12 - 188)	1 - 1620	182	52.5 (11 - 216)	0 -1814	171	37 (10 - 132)	0 - 1470	156	58 (11.5 - 204)	1 - 1453
A	246	40 (16 - 93)	0 -1109	235	23 (7 - 77)	1 -1056	238	33 (9 - 100)	0 - 758	208	27 (7 - 138)	0 - 786	221	27 (8 - 100)	1 - 918	224	30 (9 - 148)	1 - 2223

LAG(23)03



B	71	168 (49 - 384)	0 - 1813	56	57 (15 - 132)	2 - 1518	64	66 (18.5 - 167.5)	2 - 865	60	66(21.5- 279.5)	2 - 1335	57	33 (9 - 103)	2 - 592	49	50 (23 - 173)	2 - 2099
AB	20	25.5 (7.5 - 66)	0 - 148	36	39.5 (13 - 93)	1 - 466	43	19 (4 - 43)	1 - 201	26	34 (15 - 83)	5 - 340	32	24 (8 - 57)	2 - 388	20	11 (5.5 - 25.5)	1 - 63



Table 18 Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2023, as at 27 April 2023

	LAG(23)03																	
	2017/18			2018/19			2019/20			2020/21			2021/22			2022/23		
	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range
Overall	186	41.5 (14 - 142)	0 - 875	182	53 (20 - 128)	0 - 607	170	52 (19 - 142)	2 - 693	110	90.5 (29 - 205)	2 - 1278	189	98 (38 - 163)	1 - 923	243	132 (50 - 306)	1 - 1242
Type of patient																		
CLD	123	41 (13 - 143)	0 - 875	87	55 (19 - 125)	0 - 561	107	50 (15 - 147)	2 - 693	72	104.5(35.5-205.5)	2 - 1101	104	102 (29.5-178)	1 - 923	145	139 (49 - 328)	1 - 1242
HCC	52	39.5 (16.5 - 110)	1 - 691	83	49 (20 - 148)	2 - 607	58	66.5 (35 - 135)	4 - 322	33	73 (29 - 144)	5 - 1278	73	95 (45 - 157)	2 - 822	84	122 (47 - 269.5)	2 - 868
VS	9	222 (32 - 347)	7 - 870	5	98 (72 - 300)	5 - 306	1	559	599	2	218 (215 - 221)	215 - 221	8	154 (103.5 - 254.5)	70 - 396	12	191.5 (68 - 238)	51 - 636
ACLF	0	-	-	0	-	-	0	-	-	0	-	-	1	2	2	0	-	-
HCC downstaging	2	53 (51 - 55)	51-55	7	47 (17 - 84)	11 - 323	4	21 (12 - 35.5)	12 - 41	3	72 (27 - 216)	27 - 216	3	52 (24 - 143)	24 - 143	2	102.5 (94 - 111)	94 - 111
Centre																		
Newcastle	5	106 (85 - 304)	5 - 347	3	304 (22- 452)	22 - 452	4	144.5 (119 - 371)	103 - 588	2	110 (4 - 216)	4 - 216	13	152 (117 - 394)	5 - 817	14	173 (47 - 247)	26 - 770
Leeds	26	77.5 (13 - 297)	0 - 875	21	36 (12 - 99)	2 - 517	21	36 (12 - 73)	2 - 565	15	56 (26 - 133)	5 - 511	16	115.5 (52 - 147)	4 - 923	26	118.5 (46 - 362)	13 - 868
Cambridge	32	60 (28.5 - 151.5)	0 - 870	40	57.5 (21.5- 128)	2 - 355	33	35 (14 - 78)	2 - 479	35	89 (46 - 211)	5 - 625	48	63 (21.5 - 142.5)	1 - 822	53	111 (29 - 213)	1 - 832
Royal Free	13	62 (24 - 234)	3 - 369	28	56.5 (29.5- 144)	2 - 323	37	55 (23 - 135)	4 - 693	11	57 (23 - 205)	11 - 227	23	94 (27 - 148)	8 - 327	18	139.5 (67 - 388)	5 - 911
Kings College	46	67 (27 - 205)	4 - 691	38	72.5(34- 180)	4 - 607	37	84 (38 - 198)	3 - 559	31	123 (54 - 189)	8 - 1101	46	133.5 (52 - 162)	1 - 342	51	198 (92 - 341)	1 - 716
Birmingham	52	22.5 (13 - 42.5)	0 - 511	39	34 (14 - 80)	0 - 487	33	50 (30 - 125)	2 - 267	11	115 (7 - 221)	2 - 259	25	94 (60 - 218)	12 - 418	54	111 (42 - 258)	2 - 1039
Edinburgh	12	41.5 (10 - 94.5)	0 - 783	13	71 (38 - 333)	6 - 383	5	51 (44 - 151)	40 - 224	5	42 (30 - 777)	27 - 1278	18	52.5 (16 - 151)	2 - 738	27	137 (38 - 471)	2 - 1242
Recipient blood group																		
O	95	62 (16 - 245)	0 - 875	79	69 (28 - 175)	0 - 561	68	69 (19 - 163.5)	2 - 693	52	115.5 (28 - 222)	7 - 1278	88	117 (45.5- 182.5)	1 - 822	115	158 (75 - 355)	1 - 1242
A	70	29 (10 - 65)	0 - 351	75	37 (17 - 78)	2 - 457	80	50 (19 - 100.5)	2 - 588	49	78 (26 - 189)	2 - 530	77	93 (28 - 143)	2 - 476	90	104.5 (42 - 236)	2 - 911
B	18	55 (19 - 262)	4 - 783	21	103 (30- 171)	4 - 607	18	87 (43 - 183)	2 - 479	7	92 (57 - 119)	29 - 446	23	86 (40 - 271)	1 - 923	33	147 (64 - 258)	4 - 868
AB	3	27 (9 - 111)	9 - 111	7	23 (9 - 94)	6 - 111	4	7.5 (6.5 - 22)	6 - 36	2	60.5 (48 - 73)	48 - 73	1	77	77	5	2 (2 - 41)	1 - 60

3.6.6. **Figure 16** show the overall cold ischaemia time for the time periods of interest for DBD transplants while **Figure 17** shows the cold ischaemia time for each centre. **Figures 18** and **Figure 19** show the equivalent information for DCD donor transplants.

3.6.7. There were statistically significant differences in the cold ischaemia time for adult elective DBD and DCD transplants over the time periods of interest ($p=0.004$ for DBD and $p=0.014$ for DCD). However, it should be noted that these results will change as NHSBT has not received all the first week transplant record forms which collect the cold ischaemia time. It should also be noted that this analysis does not adjust for whether machine perfusion was used.





3.7. NINETY-DAY POST-TRANSPLANT SURVIVAL

3.7.1. **Figure 20** shows the unadjusted ninety-day patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first sixty months of NLOS. **Table 18** and **Table 19** shows the survival estimates and confidence intervals by blood group and type of patient for DBD and DCD transplants respectively. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.

3.7.2. For DBD transplants, there was no overall statistically significant difference between the time periods of interest in ninety-day patient survival (log-rank p-value=0.33). There was a statistically significant difference in ninety-day survival for HCC patients (log-rank p-value=0.01) and CLD patients (log-rank p-value=0.04). There were no statistically significant differences between the time periods for the individual centres and blood groups (log-rank p-value \geq 0.22), apart from blood group B patients which had significance ($p=0.03$).

3.7.3. For DCD transplants, there was overall only borderline statistically significant difference at a 5% significance level overall between the time periods in ninety-day patient survival (log-rank p-value=0.08). There was a borderline statistically significant difference in ninety-day survival for HCC patients (log-rank p-value=0.06) and CLD patients had no statistical significance (log-rank p-value=0.46). There were no statistically significant differences between the time periods for blood groups (log rank p-value \geq 0.51) and for the individual centres (log rank p-value \geq 0.20).

Figure 20 Unadjusted ninety day patient survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 December 2022




Table 18 90-day patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 December 2022


	No at risk	2017/18 % (95% CI)	No at risk	2018/19 % (95% CI)	No at risk	2019/20 % (95% CI)	No at risk	2020/21 % (95% CI)	No at risk	2021/22 % (95% CI)	No at risk	2022/23 % (95% CI)	Log-rank p-value
Overall	579	96.2 (94.3, 97.5)	567	96.5 (94.6, 97.7)	556	98.2 (96.7, 99.0)	419	97.1 (95,98.4)	450	97.8 (95.9,98.8)	303	96.6 (93.8,98.2)	0.34
Type of patient													
CLD	425	95.5 (93.1, 97.1)	436	95.9 (93.5, 97.4)	424	98.1 (96.3,99.1)	345	98.3 (96.2,99.2)	373	98.1 (96.1,99.1)	248	98 (95.2,99.2)	0.04
HCC	104	98.1 (92.5, 99.5)	71	97.2 (89.2, 99.3)	80	98.8 (91.5, 99.8)	53	90.6 (78.8,96.0)	38	97.4 (82.8,99.6)	30	86.4 (67.7,94.7)	0.01
VS	45	97.8 (85.3, 99.7)	55	100 (-)	47	97.9 (85.8, 99.7)	18	94.4 (66.6, 99.2)	27	95.7 (72.9,99.4)	17	100 (-)	0.67
HCC downstaging	5	-	5	-	5	-	3	-	2	-	0	-	-
ACLF	0	100 (-)	0	100 (-)	0	100 (-)	0	100 (-)	10	90.0 (47.3, 98.5)	8	87.5 (38.7,98.1)	0.90
Recipient blood group													
O	272	95.2 (91.9, 97.2)	266	97.4 (94.5,98.7)	241	98.8 (96.2, 99.6)	162	97.5 (93.5,99.1)	161	97.5 (93.4,99)	107	97.2 (91.5,99.1)	0.29
A	224	96.4 (93.0, 98.2)	214	96.3 (92.7,98.1)	216	97.7 (94.5, 99.0)	182	96.2 (92.1, 98.1)	202	98 (94.8,99.2)	149	97.3 (93,99)	0.83
B	66	100 (-)	53	92.5 (81.1, 97.1)	59	98.3 (88.6, 99.8)	51	98.0 (86.9,99.7)	55	100 (-)	34	91.1 (74.8,97)	0.03
AB	17	94.1 (65.0, 99.1)	34	97.1 (80.9, 99.6)	40	97.5 (83.5,99.6)	24	100 (-)	32	93.8 (77.3, 98.4)	13	100 (-)	0.74
Centre													
Newcastle	26	92.3 (72.6, 98.0)	22	95.5 (71.9, 99.3)	24	95.8 (73.9, 99.4)	24	100 (-)	23	100 (-)	9	100 (-)	0.58
Leeds	101	93.1 (86.0, 96.6)	59	91.5 (80.8, 96.4)	73	98.6 (90.7,99.8)	62	95.2 (85.7,98.4)	57	94.7 (84.4,98.3)	43	95.3 (82.7,98.8)	0.55
Cambridge	67	97.0 (88.6, 99.2)	61	100 (-)	58	94.8 (84.8, 98.3)	28	100 (-)	50	100 (-)	28	100 (-)	0.17
Royal Free	82	96.3 (89.1, 98.8)	80	93.8 (85.6, 97.3)	88	100 (-)	50	98.0 (86.6, 99.7)	61	96.7 (87.5, 99.2)	49	98 (86.4,99.7)	0.30
Kings College	111	98.2 (92.9, 99.5)	128	99.2 (94.6, 99.9)	133	98.5 (94.1, 99.6)	104	99.0 (93.4, 99.9)	109	98.1 (92.8,99.5)	59	100 (-)	0.89
Birmingham	117	95.7 (90.0, 98.2)	133	96.2 (91.2,98.4)	135	99.3 (94.9, 99.9)	96	95.8 (89.3, 98.4)	113	97.3 (92.0, 99.1)	85	95.2 (87.8,98.2)	0.53
Edinburgh	75	98.7 (90.9, 99.8)	84	96.4 (89.3,98.8)	45	95.6 (83.4, 98.9)	55	94.4 (83.6, 98.2)	37	100 (-)	30	90.0 (72.1,96.7)	0.22

Table 19 90-day patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 December 2022

	No at risk	2017/18 % (95% CI)	No at risk	2018/19 % (95% CI)	No at risk	2019/20 % (95% CI)	No at risk	2020/21 % (95% CI)	No at risk	2021/22 % (95% CI)	No at risk	2022/23 % (95% CI)	Log-rank p-value
Overall	183	98.4 (95.0, 99.5)	177	94.9 (90.5, 97.3)	166	94.6 (89.8, 97.1)	103	98.0 (92.3, 99.5)	182	98.4 (95.0, 99.5)	176	98.2 (94.6,99.4)	0.08
Type of patient													
CLD	120	98.3 (93.5, 99.6)	82	95.1 (87.5, 98.1)	103	97.1 (91.2, 99.1)	65	98.5 (89.6, 99.8)	98	99.0 (93.0,99.9)	101	99 (93.2,99.9)	0.46
HCC	52	98.1 (87.1, 99.7)	83	95.2 (87.7, 98.2)	58	89.7 (78.4, 95.2)	33	97.0 (80.4,99.6)	72	100 (-)	64	96.7 (87.3,99.2)	0.06
VS	9	100 (-)	4	100 (-)	1	100 (-)	2	100 (-)	8	87.5 (38.7, 98.1)	9	100 (-)	0.68
HCC downstaging	2	100 (-)	7	85.7 (33.4, 97.9)	4	100 (-)	3	100 (-)	3	100 (-)	2	100 (-)	0.85
ACLF	0	-	0	-	0	-	0	-	1	100 (-)	0	-	0.85
Recipient blood group													
O	95	97.9 (91.8, 99.5)	78	93.6 (85.3, 97.3)	67	94.0 (84.9, 97.7)	48	95.6 (83.6, 98.9)	85	98.8 (91.9,99.8)	78	98.6 (90.7,99.8)	0.26
A	67	98.5 (89.9, 99.8)	72	98.6 (90.5,99.8)	78	94.9 (86.9, 98.0)	46	100 (-)	74	97.3 (89.6,99.3)	72	98.6 (90.4,99.8)	0.45
B	18	100 (-)	20	90.0 (65.6, 97.4)	18	94.4 (66.6, 99.2)	7	100 (-)	22	100 (-)	23	95.7 (72.9,99.4)	0.52
AB	3	100 (-)	7	85.7 (33.4, 97.9)	3	100 (-)	2	100 (-)	1	100 (-)	3	100 (-)	0.89
Centre													
Newcastle	4	-	3	-	4	-	2	-	13	-	6	-	-
Leeds	26	96.2 (75.7, 99.4)	20	95.0 (69.5, 99.3)	21	90.5 (67.0, 97.5)	15	100 (-)	16	100 (-)	17	100 (-)	0.53
Cambridge	30	96.7 (78.6, 99.5)	37	97.3 (82.3, 99.6)	31	93.5 (76.6, 98.3)	29	100 (-)	43	95.3 (82.7,98.8)	40	100 (-)	0.55
Royal Free	13	100 (-)	28	92.9 (74.3, 98.2)	36	94.4 (79.6, 98.6)	11	80.8 (42.3, 94.9)	22	100 (-)	15	86.7 (56.4,96.5)	0.30
Kings College	46	100 (-)	37	94.6 (80.1, 98.6)	36	97.2 (81.9, 99.6)	30	100 (-)	46	100 (-)	38	97 (80.4,99.6)	0.34
Birmingham	52	98.1 (87.1, 99.7)	39	92.3 (78.0,97.5)	33	97.0 (80.4, 99.6)	11	100 (-)	25	100 (-)	42	100 (-)	0.26
Edinburgh	12	100 (-)	13	100 (-)	5	80.0 (20.4, 96.9)	5	-	17	94.1 (65.0,99.1)	18	100 (-)	0.17

3.7.4. **Figure 21** shows the unadjusted ninety-day transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first sixty months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 90 days.

3.7.5. There were no statistically significant differences in the unadjusted ninety-day transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.45 and 0.46).



3.8 ONE-YEAR POST-TRANSPLANT SURVIVAL

- 3.8.1 **Figure 22** shows the unadjusted one-year patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first forty-eight months of NLOS. **Table 20** and **Table 21** shows the survival estimates and confidence intervals by blood group and type of patient, for DBD and DCD transplants respectively. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.
- 3.8.2 For DBD transplants, there was no overall statistically significant difference between the time periods of interest in one-year patient survival (log-rank p-value=0.12). There was a statistically significant difference in one-year survival for CLD patients (log-rank p-value=0.03). There were no statistically significant difference between the blood groups (log-rank p-value \geq 0.22) and for the individual centres (log-rank p-value \geq 0.14).
- 3.8.3 For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in one-year patient survival (log-rank p-value=0.41). There were no statistically significant differences between the two time periods for CLD and HCC (log rank p-value \geq 0.34), blood groups (log rank p-value \geq 0.32) and for the individual centres (log rank p-value \geq 0.26).




Table 20 1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2022


	No at risk on day 0	2017/18 % (95% CI)	No at risk on day 0	2018/19 % (95% CI)	No at risk on day 0	2019/20 % (95% CI)	No at risk on day 0	2020/21 % (95% CI)	No at risk on day 0	2021/22 % (95% CI)	Log-rank p-value
Overall	579	94.6 (92.5, 96.2)	567	94.5 (92.2, 96.1)	556	96.0 (94.0,97.4)	419	96.4 (94.1,97.8)	227	91.6 (86.5,94.8)	0.12
Type of patient											
CLD	425	93.9 (91.1, 95.8)	436	94.5 (91.9, 96.3)	424	96.7 (94.5,98)	345	97.4 (95.0,98.6)	194	91.8 (86.1,95.2)	0.03
HCC	104	96.1 (89.9, 98.5)	71	92.9 (83.8, 97.0)	80	93.6 (85.3, 97.3)	53	90.6 (78.8,96.0)	19	89.2 (63.1,97.2)	0.60
VS	45	97.8 (85.3, 99.7)	55	96.3 (86.0, 99.1)	47	93.6 (81.4, 97.9)	18	94.4 (66.6, 99.2)	11	90.0 (47.3, 98.5)	0.76
HCC downstaging	5	-	5	-	5	-	3	-	0	-	-
Recipient blood group											
O	272	93.7 (90.1, 96.1)	266	93.9 (90.3,96.2)	241	96.7 (93.4,98.3)	162	96.9 (92.7,98.7)	74	91.5 (82.0,96.1)	0.22
A	224	95.1 (91.3, 97.3)	214	95.8 (92.1,97.8)	216	94.9 (90.9,97.1)	182	95.0 (90.6,97.4)	109	91.0 (81.8,95.7)	0.75
B	66	97.0 (88.4, 99.2)	53	92.5 (81.1, 97.1)	59	96.6 (87.1, 99.1)	51	98.0 (86.9,99.7)	26	95.0 (69.5,99.3)	0.63
AB	17	94.1 (65.0, 99.1)	34	94.0 (78.2, 98.5)	40	97.5 (83.5,99.6)	24	100 (-)	18	88.9 (62.4, 97.1)	0.46
Centre											
Newcastle	26	92.3 (72.6, 98.0)	22	95.5 (71.9, 99.3)	24	91.7 (70.6, 97.8)	24	100 (-)	11	100 (-)	0.58
Leeds	101	91.1 (83.6, 95.3)	59	89.8 (78.6, 95.3)	73	95.9 (87.8,98.7)	62	95.2 (85.7,98.4)	27	81.5 (61.1,91.8)	0.14
Cambridge	67	95.5 (86.8, 98.5)	61	100 (-)	58	93.1 (82.6, 97.3)	28	100 (-)	29	96.6 (77.9,99.5)	0.23
Royal Free	82	95.1 (87.5, 98.1)	80	91.3 (82.5, 95.7)	88	96.5 (89.5, 98.8)	50	98.0 (86.6, 99.7)	29	93.1 (75.1, 98.2)	0.43
Kings College	111	98.2 (92.9, 99.5)	128	96.8 (91.7, 98.8)	133	98.5 (94.1, 99.6)	104	95.6 (88.5, 98.3)	60	94.8 (84.8,98.3)	0.50
Birmingham	117	93.2 (86.8, 96.5)	133	94.7 (89.2,97.4)	135	95.5 (90.2, 97.9)	96	95.8 (89.3, 98.4)	53	90.1 (77.8, 95.8)	0.35
Edinburgh	75	96.0 (88.1, 98.7)	84	92.8 (84.7,96.7)	45	95.6 (83.4, 98.9)	55	94.1 (82.8, 98.1)	18	100 (-)	0.77

Table 21 1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2022

	No at risk	2017/18 % (95% CI)	No at risk	2018/19 % (95% CI)	No at risk	2019/20 % (95% CI)	No at risk	2020/21 % (95% CI)	No at risk	2021/22 % (95% CI)	Log- rank p- value
Overall	183	95.6 (91.4, 97.8)	177	92.6 (87.6,95.6)	166	92.7 (87.6, 95.8)	103	94.9 (88.3,97.9)	86	97.6 (90.8,99.4)	0.41
Type of patient											
CLD	120	96.7 (91.3, 98.7)	83	92.8 (84.6,96.7)	103	95.1 (88.6, 97.9)	65	95.1 (85.6, 98.4)	44	97.7 (84.9,99.7)	0.68
HCC	52	92.2 (80.5, 97.0)	83	92.7 (84.4, 96.6)	58	87.9 (76.3, 94.1)	33	93.7 (77.2,98.4)	36	100 (-)	0.34
VS	9	-	4	-	1	-	2	-	4	-	-
HCC downstaging	2	100 (-)	7	85.7 (33.4, 97.9)	4	100 (-)	3	100 (-)	1	100 (-)	0.84
Recipient blood group											
O	95	96.8 (90.5, 99.0)	78	92.3 (83.6, 96.4)	67	94.0 (84.9, 97.7)	48	95.6 (83.6, 98.9)	45	100 (-)	0.32
A	67	95.4 (86.5, 98.5)	72	95.8 (87.6,98.6)	78	91.0 (82.0,95.6)	46	95.6 (83.4,98.9)	28	96.4 (77.2, 99.5)	0.64
B	18	94.4 (66.6, 99.2)	20	90 (65.6, 97.4)	18	94.4 (66.6, 99.2)	7	85.7 (33.4, 97.9)	13	92.3 (56.6,98.9)	0.94
AB	3	66.7 (5.4, 94.5)	7	71.4 (25.8, 92.0)	3	100 (-)	2	100 (-)	0	100 (-)	0.64
Centre											
Newcastle	4	-	3	-	4	-	2	-	6	-	-
Leeds	26	92.3 (72.6, 98.0)	20	89.7 (64.8, 97.3)	21	85.4 (61.3, 95.1)	15	100 (-)	8	100 (-)	0.53
Cambridge	30	96.7 (78.6, 99.5)	37	94.6 (80.1, 98.6)	31	90.3 (72.9, 96.8)	29	100 (-)	19	100 (-)	0.32
Royal Free	13	92.3 (56.6, 98.9)	28	85.7 (66.3, 94.4)	36	91.6 (76.1, 97.2)	11	69.3 (31.2, 89.1)	11	90.9 (50.8,98.7)	0.48
Kings College	46	95.5 (83.0, 98.8)	37	94.6 (80.1, 98.6)	36	97.2 (81.9, 99.6)	30	91.7 (70.2, 97.9)	23	100 (-)	0.83
Birmingham	52	96.2 (85.5, 99.0)	39	92.3 (78,97.5)	33	97.0 (80.4, 99.6)	11	100 (-)	10	100 (-)	0.68
Edinburgh	12	100 (-)	13	100 (-)	5	80 (20.4, 96.9)	5	100 (-)	9	88.9 (43.3, 98.4)	0.26

3.8.4 **Figure 23** shows the unadjusted one-year transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first forty-eight months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 1 year.

3.8.5 There were no statistically significant differences in the unadjusted one-year transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.48 and 0.55).



4 CONCLUSIONS

The new National Liver Offering Scheme was implemented on the 20th March 2018 and updated on 4th October 2022. 4367 DBD and 4353 DCD livers were offered for transplantation in the first sixty months of the scheme. Of the DBD livers offered, 3810 (87%) were retrieved for the purposes of transplantation and 3294 (86%) were transplanted (all but 22 were transplanted in the UK).

Rhiannon Taylor, Maria Jacobs and Suzie Phillips
Statistics and Clinical Research

May 2023

APPENDIX A: SUPER-URGENT CATEGORIES

INDICATION FOR REGISTRATION

- 1 - Category 1: Aetiology: Paracetamol poisoning: pH <7.25 more than 24 hours after overdose and after fluid resuscitation
- 2 - Category 2: Aetiology: Paracetamol poisoning: Co-existing prothombin time >100 seconds or INR >6.5, and serum creatinine >300 µmol/l or anuria, and grade 3-4 encephalopathy
- 3 - Category 3: Aetiology: Paracetamol poisoning: Significant liver injury and coagulopathy following exclusion of other causes of hyperlactatemia (e.g. pancreatitis, intestinal ischemia) after adequate fluid resuscitation: arterial lactate >5 mmol/l on admission and >4 mmol/l 24 hours later in the presence of clinical hepatic encephalopathy
- 4 - Category 4: Aetiology: Paracetamol poisoning: Two of the three criteria from category 2 with clinical evidence of deterioration (eg increased ICP, FiO₂ >50%, increasing inotrope requirements) in the absence of clinical sepsis
- 5 - Category 5: Aetiology: Favourable non-paracetamol aetiologies such as acute viral hepatitis or ecstasy/ cocaine induced ALF: the presence of clinical hepatic encephalopathy is mandatory and: prothrombin time >100 seconds, or INR >6.5, or any three from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; any grade of hepatic encephalopathy with jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 6 - Category 6: Aetiology: Unfavourable non-paracetamol aetiologies such as seronegative or idiosyncratic drug reactions: a) prothrombin time >100 seconds, or INR >6.5, or b) in the absence of clinical hepatic encephalopathy then INR >2 after vitamin K repletion is mandatory and any two from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; if hepatic encephalopathy is present then jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 7 - Category 7: Aetiology: Acute presentation of Wilson's disease or Budd-Chiari syndrome. A combination of coagulopathy and any grade of encephalopathy
- 8 - Category 8: Hepatic artery thrombosis on days 0 to 21 after liver transplantation
- 9 - Category 9: Early graft dysfunction on days 0 to 7 after liver transplantation with at least two of the following: AST >10,000; INR >3.0; arterial lactate >3 mmol/l; absence of bile production
- 10 - Category 10: The total absence of liver function (eg after total hepatectomy)
- 11 - Category 11: Any patient who has been a live liver donor (NHS entitled) who develops severe liver failure within 4 weeks of the donor operation
- 20 - Category 20: Acute liver failure in children under two years of age: INR >4 or grade 3-4 encephalopathy. Definition: Multisystem disorder in which severe acute impairment of liver function with or without encephalopathy occurs in association with hepatocellular necrosis in a child with no recognised underlying chronic liver disease. Children with leukaemia/lymphoma, haemophagocytosis and disseminated intra-vascular coagulopathy are excluded

APPENDIX B: SIX MONTH REGISTRATION OUTCOME





Figure B3 Six month registration outcome for active elective liver and liver/kidney patients, by first transplant or regraft, 20 September 2016 to 19 September 2022






Figure B4 Six month registration outcome for active elective liver and liver/kidney patients, by sex, 20 September 2016 to 19 September 2022





APPENDIX C: ONE YEAR REGISTRATION OUTCOME

Figure C1 One year registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 March 2016 to 19 March 2022




Figure C2 One year registration outcome for active elective liver and liver/kidney patients, by age group, 20 March 2016 to 19 March 2022




Figure C3 One year registration outcome for active elective liver and liver/kidney patients, by first transplant or re-graft, 20 March 2016 to 19 March 2022




Figure C4 One year registration outcome for active elective liver and liver/kidney patients, by sex, 20 March 2016 to 19 March 2022

